Spreadsheet: 96448d1295859018-settings-changed-for-default-cell-format-want-to-change-it-back-to-general-excelforum_yongsonneedshelp
Sheet: financing basis

 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0000_BIOMED_SHOW_Financings
Lead Investor Segment | Lead Investor Continent | [NAME] Amount 2Years Rank | [NAME] Amount 2Years |  | public EU Rank | public global Rank |  | public EU Amount | public global Amount |  | IPO EU Rank | IPO global Rank |  | IPO EU Amount | IPO global Amount |  | [NAME] Rank | VC global Rank |  | [NAME] Amount | VC global Amount |  | private EU Rank | private global Rank |  | private EU Amount | private global Amount | Country ID 2009 | Country financing (HQ) | ListUS+EUID | EU/US financing (HQ) | HQContinent | Continent | HQCountry | Country | Private | Include | IncludeCo | IncludeHQ1 | IncludeHQ2 | YEAR | Month | Quarter | Round size | AmountEURrand | CompanyStatus | Product type (disease) | BIOMEDInclude | InvesteeID | InvesteeName | LegalForm | LegalType | Ticker | StockExchange | Country | City | State | Region | Continent | [NAME] | Category | Subcategory | BiotechMainSegment | MedtechMainSegment | MainDiseaseArea | MostAdvancedStatusMANUAL | InvesteeDescription | BIO | MED | BIOSUB1 | MEDSUB1 | BIOSUB2 | MEDSUB2 | FinancingID | Headline | Status | AnnouncementDate | CompletionDate | TerminationDate | Type | Class | Currency | Amount | [NAME] | AmountUSD | Investors | LeadInvestor | Text | TherapeuticStatus | IssuedShares | IssuedPrice | Source | Revisor | DateOfRevision | Comment | HQ1ID | HQ1Name | HQ1Country | HQ1Continent | HQ2ID | HQ2Name | HQ2Country | HQ2Continent | CorporateInvestorFinancing | FamilyOfficeFinancing | Xchange | USDXchange | DateOfQuery
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 31 | Immunservice | GmbH |  |  |  | D | Hamburg | HH |  | Europe | BIO-DR | BIO | CBC | BIO-TH |  | MULTI | Phase II | Immunservice GmbH is a biopharmaceutical company focused on the development and commercialization of biomimetic treatments for cancer and infectious diseases.   Immunservice's unique biomimetic approach translates human immune hormones into well tolerated and highly effective marketable drugs that improve survival and quality of life in patients.   Immunservice's most advanced drug candidate is Pulmoleukin, a natural biomimetic interleukin-2 drug developed for inhalation use in patients with pulmonary metastatic renal cell cancer and patients with high unmet medical need. Its Pulmoleukin's inhalational use prevents patients with progressive lung tumors from suffocating. | True | False | False | False | False | False | 6088 |  | Announced | 2008-01-21 00:00:00 |  |  | VC - Seed | Venture | EUR | 0.5 | 0.5 | 0.735400018795701 | High Tech Gründerfonds |  | Seed Funding for Hamburg Immunservice GmbH from High-Tech Gründerfonds |  |  |  | Web |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 35 | CareX | S.A. | Headquarters |  |  | F | ILLKIRCH CEDEX |  |  | Europe | BIO-DR | BIO | CBC | BIO-TH |  |  |  | biopharmaceutical company with a therapeutic focus on “metabolic syndrome” | True | False | False | False | False | False | 6511 |  | Announced | 2004-03-08 00:00:00 |  |  | VC - 2nd Round | Venture | EUR | 25.21 | 25.21 | 31.3587195816718 | BioMedinvestor, Credit Agricole Private Equity, GIMV, Global Life Science Ventures, HBM Partners, Index Ventures, [NAME], Sofinnova Partners |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.24390002307306 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 35 | CareX | S.A. | Headquarters |  |  | F | ILLKIRCH CEDEX |  |  | Europe | BIO-DR | BIO | CBC | BIO-TH |  |  |  | biopharmaceutical company with a therapeutic focus on “metabolic syndrome” | True | False | False | False | False | False | 7054 |  | Announced | 2002-03-31 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 6 | 6 | 5.67360022617005 | GIMV, [NAME], Sofinnova Partners |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.945600037695009 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 36 | Cellectis | S.A. | Headquarters | ALCLS | Euronext | F | [NAME] Cedex |  | F-GP&P | Europe | BIO-GPX | BIO | CBC | BIO-STT |  |  | Preclinical | worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the [NAME] and DNA recombination. | True | False | False | False | False | False | 24546 | Cellectis S.A. received PIPE - financing | Completed | 2009-10-21 00:00:00 | 2009-10-21 00:00:00 |  | PIPE | PIPE | EUR | 22.0110002 | 22.0110002 | 30.6065403764305 |  |  | BioCentury: Cellectis raises EUR 22 million  Genome engineering company [NAME] (Euronext:ALCLS) raised EUR 22 million ($32.9 million) through the sale of 1.9 million shares at EUR 11.50 in a private placement. The price is a 17% discount to [NAME]' close of EUR 13.84 on Oct. 13, before the deal was proposed. Natixis was sole bookrunner and lead manager. On Wednesday, [NAME] was off EUR 0.46 to EUR 12.25.  Cellectis S.A. (Euronext:[NAME]), [NAME], France Business: Gene/Cell therapy, Genomics Date completed: 10/21/09 Type: Private placement Raised: €22 million ($32.9 million) Shares: 1.9 million Price: €11.50 Shares after offering: 11.6 million Placement agent: Natixis |  | 1914000 | 11.5 | BC | LH | 2009-12-21 00:00:00 | no PR |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 36 | Cellectis | S.A. | Headquarters | ALCLS | Euronext | F | [NAME] Cedex |  | F-GP&P | Europe | BIO-GPX | BIO | CBC | BIO-STT |  |  | Preclinical | worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the [NAME] and DNA recombination. | True | False | False | False | False | False | 12757 |  | Announced | 2008-10-23 00:00:00 |  |  | Grant | Grant | EUR | 7.2 | 7.2 | 10.5897602706581 | OSEO |  | [NAME], a biotechnology company engaged in developing technologies for genome engineering, has received EUR7.2 million grant from OSEO, an agency engaged in providing financial support to small and medium enterprises, and very small enterprises, under its Industrial Strategic Innovation programme (ISI). Cellectis has received the grant to develop therapeutic products to treat HIV and herpes infections, under its ACTIVE project (Application CuraTive des Infections Virales par Endonucleases). Both the partners are based in France. |  |  |  | MT |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 36 | Cellectis | S.A. | Headquarters | ALCLS | Euronext | F | [NAME] Cedex |  | F-GP&P | Europe | BIO-GPX | BIO | CBC | BIO-STT |  |  | Preclinical | worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the [NAME] and DNA recombination. | True | False | False | False | False | False | 5271 |  | Announced | 2007-02-06 00:00:00 |  |  | IPO | IPO | EUR | 24.4 | 24.4 | 33.4402008221914 |  |  | Cellectis S.A. announces the success of its initial public offering on the [NAME] market of Euronext Paris. The offer price is set at €10.25 per share Demand from institutional investors was over 6 times the number of shares offered [NAME], France - February the 6th, 2007 - Cellectis S.A., a biotechnology company specializing in genome engineering and developing a new range of products for the custom rewriting of DNA sequences for the research, healthcare and industrial sectors, today announced the final details of its initial public offering (IPO) on the [NAME] market of Euronext Paris. The company also emphasized its satisfaction with the success of the listing. The offer price has been set at €10.25 per share.Thanks to its Alternext stock market listing, Cellectis S.A. has raised a total of about €21.2 million following full exercise of the extension option but prior to deduction of commissions and fees associated with the offering and prior to the potential exercise of the overallotment option ("greenshoe"). This sum will rise to around €24.4 million if the overallotment option is fully exercised. The amount raised includes €2.7 million subscribed (as part of a reserved offering) by financial investors, the company's employees, officers & shareholders and certain individuals having contributed to Cellectis S.A.'s development. The free float will stand at around 25.3% of the company's share capital. Should the overallotment option be fully exercised, the free float will rise to 28.1% of the share capital. The offering targeted at institutional investors raised significant interest, with demand (not including current shareholders) representing about six times the allotted amount. Likewise, the retail offering for individual investors was a success, with demand representing over 12.8 million euros in value and more than 5400 orders placed. [NAME] capital increase will provide the company with additional resources for financing its operations and supporting its growth strategy, which particularly aims at establishing its technology as the benchmark in genome engineering. A 1999 Institut Pasteur spin-off, Cellectis SA (genome engineering) raised more than the €14.6mm it expected, netting €19.5[NAME] ($25.2mm) in its IPO of 2.1mm shares priced at €10.25 apiece, the high end of the anticipated €8.90-10.25 range. Its stock will trade on the [NAME] market of Euronext, Paris.;Cellectis is developing genome engineering technologies called Meganuclease enzymes, which work as molecular scissors that can--with high specificity--recognize, bind, and cut DNA, which it then inserts to modify and correct an organism's existing genes, without adding foreign genes. The company's Meganuclease Recombination Systems combine the molecular scissors technology with a DNA matrix to target and modify in vivo a specific gene of interest using the cell's own natural maintenance and repair mechanisms. Since its inception, Cellectis has raised €17.5mm in two private rounds (2000 and 2002) to support R&D and commercialization efforts. |  | 2410112 | 10.25 | BC |  |  | In January, ALCLS said it hoped to raise €16-€21.2 million ($20.7-$27.5 million) through the sale of 1.8-2.4 million shares (including an extension and an overallotment) at €8.90-€10.25 in an IPO and private placement on [NAME]'s Alternext Overallottme |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.37050003369637 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 36 | Cellectis | S.A. | Headquarters |  |  | F | [NAME] Cedex |  | F-GP&P | Europe | BIO-GPX | BIO | CBC | BIO-STT |  |  | Preclinical | worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the [NAME] and DNA recombination. | True | False | False | False | False | False | 7489 |  | Announced | 2005-04-28 00:00:00 |  |  | VC - 2nd Round | Venture | EUR | 6 | 6 | 7.46460000071188 | AGF Private Equity |  | French gene therapy company Cellectis raised Euro16mm ($15.5mm) through its second round private placement to new investors BankInvest BioMedical Venture, AGF Private Equity, funds managed by LCF Rothschild Asset Management, and [NAME] Venture.;Cellectis was formed in 1999 as a spin-off from the Institut Pasteur , the owner of key patents and technologies licensed by Cellectis, and has raised a total of Euro20[NAME] since inception. The company has discovered a way to modify meganucleases (DNA cutters) to treat viral diseases and inherited genetic disorders. Its Meganuclease Recombination System ( MRS ) physically corrects genetic errors on chromosomes without adding any foreign DNA to the cells. Cellectis develops custom-made meganucleases targeting common chronic diseases, which it outlicenses to other companies in return for fees and milestones. |  |  |  | VS |  |  | text refers to two financings |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.24410000011865 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 36 | Cellectis | S.A. | Headquarters |  |  | F | [NAME] Cedex |  | F-GP&P | Europe | BIO-GPX | BIO | CBC | BIO-STT |  |  | Preclinical | worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the [NAME] and DNA recombination. | True | False | False | False | False | False | 7055 |  | Announced | 2002-05-30 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 10 | 10 | 9.45600037695009 | AGF Private Equity, BankInvest [NAME], Edmond de Rothschild Investment Partners, Odyssee Venture |  | French gene therapy company Cellectis raised Euro16mm ($15.5mm) through its second round private placement to new investors BankInvest BioMedical Venture, AGF Private Equity, funds managed by LCF Rothschild Asset Management, and [NAME] Venture.;Cellectis was formed in 1999 as a spin-off from the Institut Pasteur , the owner of key patents and technologies licensed by Cellectis, and has raised a total of Euro20[NAME] since inception. The company has discovered a way to modify meganucleases (DNA cutters) to treat viral diseases and inherited genetic disorders. Its Meganuclease Recombination System ( MRS ) physically corrects genetic errors on chromosomes without adding any foreign DNA to the cells. Cellectis develops custom-made meganucleases targeting common chronic diseases, which it outlicenses to other companies in return for fees and milestones. |  |  |  | VS |  |  | text refers to two financings |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.945600037695009 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 36 | Cellectis | S.A. | Headquarters |  |  | F | [NAME] Cedex |  | F-GP&P | Europe | BIO-GPX | BIO | CBC | BIO-STT |  |  | Preclinical | worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the [NAME] and DNA recombination. | True | False | False | False | False | False | 8497 |  | Announced | 2000-10-15 00:00:00 |  |  | VC - Other Private Equity | Venture | EUR | 4 | 4 | 3.69439996335815 | Individual Investors |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.923599990839539 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47 | Cardio3 BioSciences | S.A. | Headquarters |  |  | B | Mont-Saint-Guibert |  |  | Europe | BIO-TE | BIO | CBC | BIO-TH |  | CARDIO | Phase III | Cardio3 BioSciences, headquartered in Mont-Saint-Guibert (Belgium), is a leading edge company founded in 2007 and focused on the research, development and commercialization of regenerative therapies of cardiovascular diseases. Our lead product, C-Cure®, is a cell therapy using autologous stem cells differentiated precursors, also called cardiopoietic cells. This second generation cell therapy was developed on extensive basic research conducted with the Cardiovascular Center of Aalst, Belgium, Mayo Clinic®, [NAME] (MN), USA and is currently being evaluated in human clinical studies. | True | False | False | False | False | False | 21263 | Cardio3 BioSciences received Loan | Completed | 2009-01-20 00:00:00 | 2009-01-20 00:00:00 |  | Debt/Loan agreement | Debt | EUR | 6.5 | 6.5 | 9.03832223157211 | Hunza Ventures, Individual Investors |  | Cardio3 BioSciences Raises €13.7 million in Series B Fundraising and [NAME]In parallel with this equity fund raising Cardio3 BioSciences has raised a further €6.5 million in cash advances from the Walloon Region General Directorate for Economy, Employment & Research. These funds, which bear no interest, become repayable on the commercialisation of C-Cure. |  |  |  | VS | LH | 2009-11-12 00:00:00 |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47 | Cardio3 BioSciences | S.A. | Headquarters |  |  | B | Mont-Saint-Guibert |  |  | Europe | BIO-TE | BIO | CBC | BIO-TH |  | CARDIO | Phase III | Cardio3 BioSciences, headquartered in Mont-Saint-Guibert (Belgium), is a leading edge company founded in 2007 and focused on the research, development and commercialization of regenerative therapies of cardiovascular diseases. Our lead product, C-Cure®, is a cell therapy using autologous stem cells differentiated precursors, also called cardiopoietic cells. This second generation cell therapy was developed on extensive basic research conducted with the Cardiovascular Center of Aalst, Belgium, Mayo Clinic®, [NAME] (MN), USA and is currently being evaluated in human clinical studies. | True | False | False | False | False | False | 22207 | Cardio3 BioSciences raises €7.2mm through its Series B round | Completed | 2009-01-20 00:00:00 | 2009-01-19 00:00:00 |  | VC - 2nd Round | Venture | EUR | 7.2 | 7.2 | 10.0116800103568 | Hunza Ventures,Life Science Research Partners,Technowal S.A., Grifols, S.A., [NAME], new undisclosed investors. |  | Cardio3 BioSciences Raises €13.7 million in Series B Fundraising and Grant Funding New Funds to Drive Clinical Development of C-Cure®, a Second-Generation Cell-Based Therapy for Heart Failure  Mont-Saint-Guibert, Belgium, 19th January 2009... Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, has raised €7.2 million in a successful Series B fund raising round.The new funds, which have come from a range of new and existing investors, will be used to finance the clinical development of the Company’s lead product. C-Cure is a unique therapy that allows the differentiation of a patient’s own cells into ‘cardiopoïetic’ cells which grow into new heart cells and repair heart muscle. C-Cure holds the promise for a treatment that could´fundamentally change the future of heart failure patients, one of the world’s largest medical needs. The Company plans to enrol shortly approximately 240 patients in a clinical trial with C-Cure to evaluate its potential in the treatment of heart failure. |  |  |  | VS | LH | 2009-11-12 00:00:00 |  |  |  |  |  |  |  |  |  | -1 | 0 | 1 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 57 | Stratec Biomedical Systems | AG | Headquarters | SBS | FWB | D | Birkenfeld | BW | D-STERN | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | designs, develops and produces fully automated systems for partners in clinical diagnostics and biotechnology.These partners, mainly global players in the in vitro diagnostics industry, sell the STRATEC analysers to laboratories and research institutes throughout the world as system solutions together with their reagents projektiert, entwickelt und produziert vollautomatische [NAME] für Partner aus der klinischen Diagnostik und Biotechnologie. Diese Partner vermarkten die Systeme weltweit als Systemlösungen, in der [NAME] gemeinsam mit ihren Reagenzien, an [NAME], [NAME] und Forschungseinrichtungen. | False | True | False | False | False | False | 3470 | Stratec Biomedical Systems and Stratec Biomedical Systems reach other agreement | Announced | 2008-06-30 00:00:00 |  |  | [NAME] |  | EUR | 2 | 2 | 2.9416000751828 |  |  | GERMANY - In June 2008. the board of STRATEC Biomedical Systems AG, a Birkenfeld-based manufacturer of automated analyzer systems, authorized the repurchase of up to 2 mil euros ($3.151 mil US) of the company's ordinary share capital, in open market transactions. |  |  |  | THO |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 57 | Stratec Biomedical Systems | AG | Headquarters | SBS | FWB | D | Birkenfeld | BW | D-STERN | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | designs, develops and produces fully automated systems for partners in clinical diagnostics and biotechnology.These partners, mainly global players in the in vitro diagnostics industry, sell the STRATEC analysers to laboratories and research institutes throughout the world as system solutions together with their reagents projektiert, entwickelt und produziert vollautomatische [NAME] für Partner aus der klinischen Diagnostik und Biotechnologie. Diese Partner vermarkten die Systeme weltweit als Systemlösungen, in der [NAME] gemeinsam mit ihren Reagenzien, an [NAME], [NAME] und Forschungseinrichtungen. | False | True | False | False | False | False | 13766 |  | Announced | 2005-09-27 00:00:00 |  |  | PIPE | PIPE | USD | 14.74 | 11.847922086 | 14.7399998685983 | - |  | Stratec Biomedical Systems AG (DB: SBS) announced a private placement of 329,989 shares at a price of €37 ($44.68) per share for gross proceeds of €12.21 million ($14.74 million) on September 27, 2005. The shares were placed with institutional investors. WestLB AG acted as the placement agent for the transaction. [NAME] of Lovells acted as legal advisor for Stratec Biomedical Systems AG. The conversion was made from oanda.com as on September 27, 2005. |  | 329989 |  | CIQ |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0.8037939 | 1.24410000011865 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 59 | TF Instruments | GmbH |  |  |  | D | Heidelberg | BW | D-RNT | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | TF Instruments develops and manufactures state-of-the-art ultrasonic resonators based on the Ultrasonic Resonator Technology (URT), with sample cells of minimal volume and the most accurate temperature control available, mainly for analytical use in the pharmaceutical industry | False | True | False | False | False | False | 7490 |  | Announced | 2006-01-15 00:00:00 |  |  | VC - 2nd Round | Venture |  |  |  |  | Individual Investors, TechnoStart |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 59 | TF Instruments | GmbH |  |  |  | D | Heidelberg | BW | D-RNT | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | TF Instruments develops and manufactures state-of-the-art ultrasonic resonators based on the Ultrasonic Resonator Technology (URT), with sample cells of minimal volume and the most accurate temperature control available, mainly for analytical use in the pharmaceutical industry | False | True | False | False | False | False | 7056 |  | Announced | 2004-07-01 00:00:00 |  |  | VC - 1st Round | Venture |  |  |  |  | Individual Investors, TechnoStart |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.24390002307306 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 59 | TF Instruments | GmbH |  |  |  | D | Heidelberg | BW | D-RNT | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | TF Instruments develops and manufactures state-of-the-art ultrasonic resonators based on the Ultrasonic Resonator Technology (URT), with sample cells of minimal volume and the most accurate temperature control available, mainly for analytical use in the pharmaceutical industry | False | True | False | False | False | False | 6917 |  | Announced | 2003-08-01 00:00:00 |  |  | VC - Seed | Venture | EUR | 0.5 | 0.5 | 0.565599988780518 | Individual Investors, TechnoStart |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.13119997756104 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 68 | [NAME] | GmbH | Headquarters |  |  | D | München | BAY |  | Europe | BIO-DR | BIO | CBC | BIO-TH |  |  |  | Die Diaferon GmbH ist ein Biotechnologie-Unternehmen, das gentechnisch hergestellte medizinische [NAME] entwickelt und daraus entsprechende Medikamente herstellt. Die Basis der [NAME] [NAME] ist eine patentierte [NAME] zur therapeutischen [NAME]. Dieses neuartige pharmakokinetische System (»drug delivery system«) [NAME], Freisetzung und [NAME] Substanzen ermöglicht eine [NAME] interessanten Anwendungen in verschiedenen [NAME], so [NAME] Verbesserung der compliance und/oder der Lebensqualität im [NAME] einer Therapie durch [NAME] anwendungs- oder wirkstoffbedingter unerwünschter Arzneimittelwirkungen. Es erlaubt darüber hinaus aber auch die [NAME], wie sie bislang nicht realisierbar [NAME], weil [NAME] nicht oder nicht in hinreichender Menge an den Ort seiner beabsichtigten Wirkung gelangen konnte. | True | False | False | False | False | False | 6087 |  | Announced | 2007-03-16 00:00:00 |  |  | VC - Seed | Venture | EUR | 0.68 | 0.68 | 0.931940022913531 | High-Tech Gründerfonds, Bayern Kapital, The Bioscience Ventures Group |  |  |  |  |  | Web |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.37050003369637 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 87 | Kourion Therapeutics | AG |  |  |  | D |  |  |  | Europe | BIO-TE | BIO | CBC | BIO-TH |  |  |  |  | True | False | False | False | False | False | 7057 |  | Announced | 2001-06-27 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 12 | 12 | 10.7472001983245 | MPM Capital |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.895600016527043 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 | Cell Medica | Ltd. | Headquarters |  |  | UK | London |  |  | Europe | BIO-DR | BIO | CBC | BIO-TH |  | MULTI | Phase I/II | Cell [NAME] is a cell therapy company focusing on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy.   Cell [NAME]'s cellular immunotherapy technique involves harnessing and enhancing the power of the human immune system to fight disease. The company's clinical application involves protecting immunosuppressed patients at high risk of infection from cytomegalovirus (CMV) following allogeneic haematopoietic stem cell (bone marrow) transplant. These are typically leukaemia patients not responding to drug therapies. These patients undergo high dose chemotherapy and whole body irradiation to kill the cancerous leukaemia cells, but this procedure destroys the patient's natural bone marrow function which is necessary for generating red blood cells and white blood cells (immune cells). Using advanced cell formulation techniques, CMV-specific memory T cells can be recovered from a donor and infused into the patient to restore immunity to CMV.   Cell Medica's research partners include: The Royal Free Hospital, University College London, Imperial College London and the University of Wurzburg. Cell [NAME] is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease. Cell [NAME] is a partnership of clinicians, scientists, universities, and investors working together to make the unique benefits of T cell immunotherapy available to patients on a routine basis rather than being confined to a few research hospitals in a clinical trial setting. | True | False | False | False | False | False | 21266 | Cell Medica Ltd. received Second Round | Completed | 2009-09-21 00:00:00 | 2009-09-21 00:00:00 |  | VC - 2nd Round | Venture | GBP | 1.95 | 2.1897915 | 3.04492941491656 | Imperial Innovations Group plc, Private investors | Imperial Innovations | Funding will be used to commercialize a cell therapy technique which protects patients with weakened immune systems against cytomegalovirus (CMV) infections, particularly after bone marrow transplants. |  |  |  | VS |  |  | no PR found |  |  |  |  |  |  |  |  | 0 | 0 | 1.12297 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 115 | [NAME] | Ltd. | Portfolio Company |  |  | ISR | Ness [NAME] |  |  | Europe | BIO-DR | BIO | CBC | BIO-TH |  | MET | Phase III | [NAME], fully owned by Clal Biotechnology Industries, is focused on development of innovative treatment for autoimmune diabetes. The company lead product is [NAME], a novel therapeutic approach in treating type 1 diabetes (T1D), is currently in phase III clinical studies. It is a unique peptide derived from the human protein, HSP60, which immunomodulates the immune system, prevents the destruction of pancreatic cells that secrete insulin and preserves their natural function. [NAME] will continue the ongoing phase III study for [NAME], a synthetic peptide immunomodulator, which is being developed exclusively by DeveloGen for the treatment of type 1 diabetes. The product is currently in phase III clinical development in a global study being carried out in Europe, South Africa and Israel. In patients with type 1 diabetes the immune system destroys the insulin-producing beta-cells of the pancreas, resulting in diminished and eventually non-existent insulin production and a life-long dependence on exogenous insulin therapy. To date there is no safe and effective way of stopping the immune destruction and curing the disease. | True | False | False | False | False | False | 33071 | Teva Pharmaceutical and Clal Biotechnology invest in [NAME] | Completed | 2010-06-17 00:00:00 | 2010-06-17 00:00:00 |  | VC Corporate - Company | Venture | USD | 17.5 | 13.2104 | 17.4999997430987 | Clal Biotechnology Industries Ltd, Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | Teva Pharmaceutical Industries Limited, a pharmaceutical company, has exercised its option to invest in Andromeda Biotech, Ltd., a wholly-owned subsidiary of Clal Biotechnology Industries, Ltd. Both Teva Pharmaceutical and [NAME] are based in Israel. Pursuant to the exercise of the option, Teva and Clal Biotechnology Industries (CBI) will invest an additional total of $17.5 million in Andromeda. [NAME] will invest $11.9 million and $5.6 million by CBI. The transaction is a part of [NAME] exclusively licensed [NAME] lead product, [NAME] for the treatment of type 1 diabetes and received worldwide marketing rights for the product. [NAME], Israel, June 17, 2010: Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd. (“Andromeda”) at a company per-money valuation of 170 million US dollars. [NAME] exclusively licensed [NAME]’s lead product, [NAME] for the treatment of type 1 diabetes and received worldwide marketing rights for the product. Pursuant to the exercise of the option, Teva and Clal Biotechnology Industries (CBI) will invest an additional total of 17.5 million US dollars in [NAME] (11.9 M US$ by Teva, 5.6 M US$ by CBI). This investment will be utilized by [NAME] to perform DIA-AID 2, a confirmatory Phase III clinical study using [NAME] for the treatment of newly diagnosed type 1 diabetes patients. |  |  |  | MT | EMH |  |  | 30724 | Clal Biotechnology Industries | ISR | Europe |  |  |  |  | -1 | 0 | 0.75488 | 1.32471384235895 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 118 | [NAME] | GmbH | Headquarters |  |  | D | Darmstadt | HS |  | Europe | BIO-IVD | BIO | CBC | BIO-DIA |  | MET |  | [NAME] is a biopharmaceutical company focused on celiac disease and transglutaminases family of enzymes.   ZEDIRA produces and markets reagents for research & development as well as diagnostics pursuing independent development of active ingredients. The company conducts research on small molecules that block dysregulated transglutaminases in a targeted way. Its lead compound [NAME] for celiac disease inhibits the tissue transglutaminase in the mucosa and aims to interrupt the mechanism of gluten intolerance in a targeted way. The company's second indication area is thrombosis prophylaxis (anticoagulation), inhibiting the blood plasma transglutaminase (factor [NAME]) enabling selective intervention in the coagulation cascade. The company has developed a unique product portfolio for transglutaminase research & development. It products include: transglutaminase, protease, assays, substrates, antibodies, inhibitors, antigens and ELISA kits.   ZEDIRA has alliances with Novo-Nordisk A/S and Sanofi-Aventis. | True | False | False | False | False | False | 34863 | [NAME] takes diagnostics specialist R-Biopharm on board | Completed | 2010-05-21 00:00:00 | 2010-05-21 00:00:00 |  | VC - 1st Round | Venture | EUR | 0.5 | 0.5 | 0.662356921179475 | R-Biopharm, High-Tech Gruenderfonds Management |  | As part of a capital increase, R-Biopharm AG has acquired a minority shareholding in Zedira GmbH. With this strategic investment the diagnostics company has secured exclusive access to the celiac disease specialist’s products. High-Tech Gründerfonds has also taken part in the capital increase by investing further in Zedira. Managing partner Dr [NAME] explains the benefits for [NAME]: “Our products contribute to improving celiac disease diagnostics. In R-Biopharm we have a first-rate partner at our side who will take on the marketing of certified in-vitro diagnostic products. As an addition to its solid business involving special R&D reagents, this will further enhance the Company's independence from the capital market.” Joint managing partner Dr [NAME] adds: “Strategic partnerships are an ideal option for funding development-oriented businesses. We also see opportunity for gaining strategic partners for our active ingredient development projects involving the indication areas of celiac disease and thrombosis.” Dr [NAME], R-Biopharm AG’s managing director, summarises the reasons for this investment: “[NAME] has positioned itself as a producer of high-quality diagnostic antigens, paired with comprehensive scientific understanding of celiac disease. Its work at the interface between diagnostics and therapy generates products that are of interest to R-Biopharm because of their unique selling propositions.” [NAME], director of investment at High-Tech-Gründerfonds, rates the deal from the investor’s perspective: “R-Biopharm AG’s strategic investment represents the next step in the company's development. [NAME] proves that raising finance is achievable even in a difficult setting. We are pleased to be assisting the company in this round as well, and expect in the future to see further investor involvement or possibly a pharmaceuticals company acquiring a stake.” |  |  |  | VS | UT | 2010-11-04 00:00:00 |  |  |  |  |  |  |  |  |  | -1 | 0 | 1 | 1.32471384235895 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 118 | [NAME] | GmbH | Headquarters |  |  | D | Darmstadt | HS |  | Europe | BIO-IVD | BIO | CBC | BIO-DIA |  | MET |  | [NAME] is a biopharmaceutical company focused on celiac disease and transglutaminases family of enzymes.   ZEDIRA produces and markets reagents for research & development as well as diagnostics pursuing independent development of active ingredients. The company conducts research on small molecules that block dysregulated transglutaminases in a targeted way. Its lead compound [NAME] for celiac disease inhibits the tissue transglutaminase in the mucosa and aims to interrupt the mechanism of gluten intolerance in a targeted way. The company's second indication area is thrombosis prophylaxis (anticoagulation), inhibiting the blood plasma transglutaminase (factor [NAME]) enabling selective intervention in the coagulation cascade. The company has developed a unique product portfolio for transglutaminase research & development. It products include: transglutaminase, protease, assays, substrates, antibodies, inhibitors, antigens and ELISA kits.   ZEDIRA has alliances with Novo-Nordisk A/S and Sanofi-Aventis. | True | False | False | False | False | False | 37215 |  | Completed | 2010-01-31 00:00:00 | 2010-01-31 00:00:00 |  | Grant | Grant | EUR | 0.35 | 0.35 | 0.463649844825633 | German Ministry of Education & Research | German Ministry of Education & Research |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.32471384235895 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 118 | [NAME] | GmbH | Headquarters |  |  | D | Darmstadt | HS |  | Europe | BIO-IVD | BIO | CBC | BIO-DIA |  | MET |  | [NAME] is a biopharmaceutical company focused on celiac disease and transglutaminases family of enzymes.   ZEDIRA produces and markets reagents for research & development as well as diagnostics pursuing independent development of active ingredients. The company conducts research on small molecules that block dysregulated transglutaminases in a targeted way. Its lead compound [NAME] for celiac disease inhibits the tissue transglutaminase in the mucosa and aims to interrupt the mechanism of gluten intolerance in a targeted way. The company's second indication area is thrombosis prophylaxis (anticoagulation), inhibiting the blood plasma transglutaminase (factor [NAME]) enabling selective intervention in the coagulation cascade. The company has developed a unique product portfolio for transglutaminase research & development. It products include: transglutaminase, protease, assays, substrates, antibodies, inhibitors, antigens and ELISA kits.   ZEDIRA has alliances with Novo-Nordisk A/S and Sanofi-Aventis. | True | False | False | False | False | False | 6091 |  | Announced | 2007-10-09 00:00:00 |  |  | VC - Seed | Venture | EUR | 0.5 | 0.5 | 0.685250016848185 | High-Tech Gründerfonds |  |  |  |  |  | Web |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.37050003369637 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 128 | Urotec | GmbH | Headquarters |  |  | D | Dresden | S |  | Europe | BIO-TE | BIO | CBC | BIO-TH | MED-TH | URO | Marketed | Die Urotec GmbH ist ein Biotechnologie-Unternehmen, das seinen Fokus auf die Forschung, Entwicklung, Produktion und den Vertrieb innovativer [NAME] im Bereich des Tissue Engineering der unteren Harnorgane gerichtet hat. Als erstes Unternehmen bietet die Urotec kommerziell funktionalen, autologen (patienteneigenen) Gewebeersatz zur Rekonstruktion der [NAME] und der Harnblase an. Im Gegensatz zu den derzeit klinisch verwendeten [NAME] geben die [NAME] Urotec entwickelten autologen Gewebekonstrukte die natürlichen funktionalen [NAME] des ursprünglichen Harnröhren- und [NAME] wieder. [NAME] wird außerdem durch [NAME] Urotec hergestellten Gewebeersatz eine zusätzliche Operation zur Gewebeentnahme erspart. Da keine Abstoßreaktionen des autologen Gewebeersatzes zu erwarten sind, wird dem Patienten schnell und dauerhaft geholfen. Gleichzeitig sinken die [NAME].  Die Gründer der Urotec GmbH sind Frau Dr. med. [NAME] und Herr Sören Liebig. Dr. [NAME] ist Humanmedizinerin und Erfinderin der dem Projekt zugrunde liegenden patentierten [NAME]. [NAME] im [NAME] des urologischen Tissue engineering führte sie unter anderem an die Urologie der University of California in Los Angeles. Sie arbeitet seit über fünf Jahren in der [NAME] und ist eine der weltweit führenden Forscher im [NAME] des urologischen Tissue engineering. Sören Liebig ist Rechtsanwalt und begleitet das Projekt juristisch sowie kaufmännisch. | True | True | False | False | False | False | 22613 |  | Announced | 2009-02-09 00:00:00 |  |  | VC - 2nd Round | Venture |  |  |  |  | Technologiegrunderfonds Sachsen |  | GERMANY - TGFS invests in UroTec GmbH Early-stageMonday 9th February 2009: 15:28Technologiegrnderfonds [NAME] (TGFS) has invested in Dresden-based biotechnology company UroTec GmbH. UroTec GmH develops fuctional tissue replacements on basis of the body's tissues to reconstruct the lower urine tract. |  |  |  | MT |  |  | Amount na |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 128 | Urotec | GmbH | Headquarters |  |  | D | Dresden | S |  | Europe | BIO-TE | BIO | CBC | BIO-TH | MED-TH | URO | Marketed | Die Urotec GmbH ist ein Biotechnologie-Unternehmen, das seinen Fokus auf die Forschung, Entwicklung, Produktion und den Vertrieb innovativer [NAME] im Bereich des Tissue Engineering der unteren Harnorgane gerichtet hat. Als erstes Unternehmen bietet die Urotec kommerziell funktionalen, autologen (patienteneigenen) Gewebeersatz zur Rekonstruktion der [NAME] und der Harnblase an. Im Gegensatz zu den derzeit klinisch verwendeten [NAME] geben die [NAME] Urotec entwickelten autologen Gewebekonstrukte die natürlichen funktionalen [NAME] des ursprünglichen Harnröhren- und [NAME] wieder. [NAME] wird außerdem durch [NAME] Urotec hergestellten Gewebeersatz eine zusätzliche Operation zur Gewebeentnahme erspart. Da keine Abstoßreaktionen des autologen Gewebeersatzes zu erwarten sind, wird dem Patienten schnell und dauerhaft geholfen. Gleichzeitig sinken die [NAME].  Die Gründer der Urotec GmbH sind Frau Dr. med. [NAME] und Herr Sören Liebig. Dr. [NAME] ist Humanmedizinerin und Erfinderin der dem Projekt zugrunde liegenden patentierten [NAME]. [NAME] im [NAME] des urologischen Tissue engineering führte sie unter anderem an die Urologie der University of California in Los Angeles. Sie arbeitet seit über fünf Jahren in der [NAME] und ist eine der weltweit führenden Forscher im [NAME] des urologischen Tissue engineering. Sören Liebig ist Rechtsanwalt und begleitet das Projekt juristisch sowie kaufmännisch. | True | True | False | False | False | False | 6093 |  | Announced | 2008-03-26 00:00:00 |  |  | VC - Seed | Venture | EUR | 0.5 | 0.5 | 0.735400018795701 | High-Tech Gründerfonds |  | Mit der [NAME] soll der „proof of concept“ im [NAME] Tiermodellen und ersten [NAME] erbracht werden. Dazu sieht der [NAME] Tierversuche an 32 [NAME] und anschließend ab Februar 2009 eine humane [NAME] an ca. 5-10 Patienten vor. Des Weiteren soll eine Herstellungserlaubnis für das erste Produkt dem [NAME] erlangt werden. |  |  |  | Web |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 137 | Rodos BioTarget | GmbH | Headquarters |  |  | D | Hannover | NS |  | Europe | BIO-DD | BIO | CBC | BIO-TH |  | MULTI | Preclinical | Rodos BioTarget GmbH (RBT) is an early-stage, privately-held, venture capital-funded biotechnology company, based in Hannover, Germany. RBT has developed a novel pathway towards immune reconstitution and disease control employing cell-targeted nanocarriers - ‘TargoSpheres®’ - to channel potent bioactive agents into intracellular pathways of cells that direct the antigen-specific immune response. This permits a restoration of immune competence in a variety of disease states as well as providing innovative interventions against various infectious diseases and cancers. RBT’s initial development program is directed at eliminating intracellular reservoirs of the human immunodeficiency and hepatitis C viruses as well as restoring immune competence against hepatocellular carcinoma and colorectal adenocarcinoma.  Having achieved an effective nanocarrier targeting technology directed at antigen-presenting cells, RBT also collaborates with partners in the pharmaceutical industry to achieve improved vaccine responses in a variety of other cancers and infections. Additionally, in partnering with established pharmaceutical enterprises, RBT’s broad application platform shall be applied to life-cycle management as well as to improving the efficacy of existing treatments in multiple disease entities, thereby broadening its overall marketing potential. | True | False | False | False | False | False | 14498 | Rodos BioTarget completes its seed round | Announced | 2009-05-07 00:00:00 |  |  | VC - Seed | Venture | EUR | 0.5 | 0.5 | 0.695255556274778 | Enjoyventure Management GmbH; High-Tech Gründerfonds Management GmbH; hannoverimpuls GmbH | Enjoyventure Management GmbH | Hannover/Bonn, 07. Mai 2009. Die Rodos BioTarget GmbH (RBT) schließt erfolgreich eine Start-up-Finanzierungsrunde mit [NAME] und dem hannover innovations fonds (hif) ab |  |  |  | Web |  |  | UT20100519: Amount aus transkript 05/2010, Seite 32 |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150 | Quantifoil Micro Tools | GmbH |  |  |  | D | Jena | TH | D-BIJ | Europe | INS | INS |  |  |  |  |  | QUANTIFOIL Micro Tools GmbH manufactures and markets its proprietary QUANTIFOIL® support foils for electron microscopy.   QUANTIFOIL is the only manufacturer of perforated support foils with pre-defined hole size, shape and arrangement which are used in electron microscopy. In this way, QUANTIFOIL has become the market leader of support films for cryo-electron microscopy. Our products greatly simplify specimen preparation and allow image acquisition to be performed automatically. QUANTIFOIL® support films are produced using technologies that are protected by internationally issued patents. | False | False | False | False | False | False | 19979 | Analytik Jena AG acquired an approximately 25% stake in QUANTIFOIL Instruments GmbH, | Completed | 2009-07-14 00:00:00 | 2009-07-14 00:00:00 |  | Minority acquisition | Strategic Investment |  |  |  |  |  |  | GERMANY - Analytik Jena AG acquired an approximately 25% stake in QUANTIFOIL Instruments GmbH, a [NAME] based manufacturer and wholesaler of laboratory equipment. |  |  |  | THO | LH | 2009-11-27 00:00:00 |  |  |  |  |  |  |  |  |  | -1 | 0 |  | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 156 | Miacom diagnostics | GmbH |  |  |  | D | [NAME] | NRW |  | Europe | BIO-IVD | BIO | CBC | BIO-DIA |  |  |  | Testsysteme zum molekularen Nachweis von krank machenden Keimen. [NAME] erfolgt direkt [NAME] Probenmaterial wie [NAME], [NAME] und Blutkultur innerhalb von 30 Minuten. [NAME] mussten Patienten bisher tagelang warten. Mit dieser schnellen Methode ist es erstmals denkbar, eine Antibiotika-Therapie gezielt, basierend auf [NAME], [NAME]. Dieses ist besonders für die Notfall-Diagnostik und zur Unterstützung der [NAME]Interesse. Die schnellere gezielte Therapie kann nicht nur Leben retten, sondern auch dem [NAME] erhebliche [NAME] sparen. | True | False | False | False | False | False | 22833 | Miacom Diagnostics GmbH received Venture Capital-Financing | Completed | 2009-04-17 00:00:00 | 2009-04-17 00:00:00 |  | VC - Unknown | Venture |  |  |  |  | Inveni Capital | Inveni Capital |  |  |  |  | CIQ |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 165 | PolyAn | GmbH |  |  |  | D | Berlin | B | D-BB | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | first high-throughput synthetic biochips, highly selective membranes for the petrochemical industry, surfaced immobilized catalysts Cor Competencies: Molecular Surface Engineering (MSE) und dem Surface Molecular Imprinting (SMI),   --> Materialoberflächen mit speziellen chemischen Strukturen versehen und [NAME]. die Ausbeute und Reproduzierbarkeit analytischer [NAME]. Die MSE-Technologie setzt dort an, wo andere [NAME] ihre Grenzen zeigen. erview: Provider of molecular surface engineering technology (MSE). The company provides affinity-membranes, solid phase synthesis, and anti fouling-coatings for biotech-applications. The company's products are designed to improve existing processes such as high-throughput screening and array production. The company also offers synthesis, photochemistry, and analysis services. [[NAME]: nanotechnology, biochip]  Customers: The company's customers include Aral Aromatics, ARKEMA, ConocoPhillips, [NAME], Eastman Chemical Middleburg, [NAME], [NAME], Merck, Roche Diagnostics, SI Group, and Siemens.  Competition: The company's competitors include [NAME], Tosoh Biosep, [NAME], [NAME], Millipore, and Vivascience. | False | True | False | False | False | False | 7950 |  | Announced | 2005-12-28 00:00:00 |  |  | VC - 4rd Round | Venture | EUR | 0.9 | 0.9 | 1.11969000010678 | [NAME] mbH, BC Brandenburg Capital |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.24410000011865 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 165 | PolyAn | GmbH |  |  |  | D | Berlin | B | D-BB | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | first high-throughput synthetic biochips, highly selective membranes for the petrochemical industry, surfaced immobilized catalysts Cor Competencies: Molecular Surface Engineering (MSE) und dem Surface Molecular Imprinting (SMI),   --> Materialoberflächen mit speziellen chemischen Strukturen versehen und [NAME]. die Ausbeute und Reproduzierbarkeit analytischer [NAME]. Die MSE-Technologie setzt dort an, wo andere [NAME] ihre Grenzen zeigen. erview: Provider of molecular surface engineering technology (MSE). The company provides affinity-membranes, solid phase synthesis, and anti fouling-coatings for biotech-applications. The company's products are designed to improve existing processes such as high-throughput screening and array production. The company also offers synthesis, photochemistry, and analysis services. [[NAME]: nanotechnology, biochip]  Customers: The company's customers include Aral Aromatics, ARKEMA, ConocoPhillips, [NAME], Eastman Chemical Middleburg, [NAME], [NAME], Merck, Roche Diagnostics, SI Group, and Siemens.  Competition: The company's competitors include [NAME], Tosoh Biosep, [NAME], [NAME], Millipore, and Vivascience. | False | True | False | False | False | False | 7796 |  | Announced | 2004-02-15 00:00:00 |  |  | VC - 3rd Round | Venture | EUR | 0.5 | 0.5 | 0.621950011536529 | [NAME] mbH, Orthmann AG |  | Euquity, debt financing |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.24390002307306 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 165 | PolyAn | GmbH |  |  |  | D | Berlin | B | D-BB | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | first high-throughput synthetic biochips, highly selective membranes for the petrochemical industry, surfaced immobilized catalysts Cor Competencies: Molecular Surface Engineering (MSE) und dem Surface Molecular Imprinting (SMI),   --> Materialoberflächen mit speziellen chemischen Strukturen versehen und [NAME]. die Ausbeute und Reproduzierbarkeit analytischer [NAME]. Die MSE-Technologie setzt dort an, wo andere [NAME] ihre Grenzen zeigen. erview: Provider of molecular surface engineering technology (MSE). The company provides affinity-membranes, solid phase synthesis, and anti fouling-coatings for biotech-applications. The company's products are designed to improve existing processes such as high-throughput screening and array production. The company also offers synthesis, photochemistry, and analysis services. [[NAME]: nanotechnology, biochip]  Customers: The company's customers include Aral Aromatics, ARKEMA, ConocoPhillips, [NAME], Eastman Chemical Middleburg, [NAME], [NAME], Merck, Roche Diagnostics, SI Group, and Siemens.  Competition: The company's competitors include [NAME], Tosoh Biosep, [NAME], [NAME], Millipore, and Vivascience. | False | True | False | False | False | False | 7491 |  | Announced | 2003-06-04 00:00:00 |  |  | VC - 2nd Round | Venture | EUR | 0.8 | 0.8 | 0.904959982048828 | [NAME] mbH, Orthmann AG | [NAME] [NAME] mbH |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.13119997756104 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 165 | PolyAn | GmbH |  |  |  | D | Berlin | B | D-BB | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | first high-throughput synthetic biochips, highly selective membranes for the petrochemical industry, surfaced immobilized catalysts Cor Competencies: Molecular Surface Engineering (MSE) und dem Surface Molecular Imprinting (SMI),   --> Materialoberflächen mit speziellen chemischen Strukturen versehen und [NAME]. die Ausbeute und Reproduzierbarkeit analytischer [NAME]. Die MSE-Technologie setzt dort an, wo andere [NAME] ihre Grenzen zeigen. erview: Provider of molecular surface engineering technology (MSE). The company provides affinity-membranes, solid phase synthesis, and anti fouling-coatings for biotech-applications. The company's products are designed to improve existing processes such as high-throughput screening and array production. The company also offers synthesis, photochemistry, and analysis services. [[NAME]: nanotechnology, biochip]  Customers: The company's customers include Aral Aromatics, ARKEMA, ConocoPhillips, [NAME], Eastman Chemical Middleburg, [NAME], [NAME], Merck, Roche Diagnostics, SI Group, and Siemens.  Competition: The company's competitors include [NAME], Tosoh Biosep, [NAME], [NAME], Millipore, and Vivascience. | False | True | False | False | False | False | 8079 |  | Announced | 2003-06-04 00:00:00 |  |  | Debt/Loan agreement | Debt | EUR | 1.6 | 1.6 | 1.80991996409766 | [NAME] mbH, Orthmann AG | [NAME] [NAME] mbH |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.13119997756104 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 165 | PolyAn | GmbH |  |  |  | D | Berlin | B | D-BB | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | first high-throughput synthetic biochips, highly selective membranes for the petrochemical industry, surfaced immobilized catalysts Cor Competencies: Molecular Surface Engineering (MSE) und dem Surface Molecular Imprinting (SMI),   --> Materialoberflächen mit speziellen chemischen Strukturen versehen und [NAME]. die Ausbeute und Reproduzierbarkeit analytischer [NAME]. Die MSE-Technologie setzt dort an, wo andere [NAME] ihre Grenzen zeigen. erview: Provider of molecular surface engineering technology (MSE). The company provides affinity-membranes, solid phase synthesis, and anti fouling-coatings for biotech-applications. The company's products are designed to improve existing processes such as high-throughput screening and array production. The company also offers synthesis, photochemistry, and analysis services. [[NAME]: nanotechnology, biochip]  Customers: The company's customers include Aral Aromatics, ARKEMA, ConocoPhillips, [NAME], Eastman Chemical Middleburg, [NAME], [NAME], Merck, Roche Diagnostics, SI Group, and Siemens.  Competition: The company's competitors include [NAME], Tosoh Biosep, [NAME], [NAME], Millipore, and Vivascience. | False | True | False | False | False | False | 8078 |  | Announced | 2001-07-01 00:00:00 |  |  | Debt/Loan agreement | Debt | EUR | 0.5 | 0.5 | 0.447800008263521 | Innovationsfond des Landes Berlin |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.895600016527043 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 165 | PolyAn | GmbH |  |  |  | D | Berlin | B | D-BB | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | first high-throughput synthetic biochips, highly selective membranes for the petrochemical industry, surfaced immobilized catalysts Cor Competencies: Molecular Surface Engineering (MSE) und dem Surface Molecular Imprinting (SMI),   --> Materialoberflächen mit speziellen chemischen Strukturen versehen und [NAME]. die Ausbeute und Reproduzierbarkeit analytischer [NAME]. Die MSE-Technologie setzt dort an, wo andere [NAME] ihre Grenzen zeigen. erview: Provider of molecular surface engineering technology (MSE). The company provides affinity-membranes, solid phase synthesis, and anti fouling-coatings for biotech-applications. The company's products are designed to improve existing processes such as high-throughput screening and array production. The company also offers synthesis, photochemistry, and analysis services. [[NAME]: nanotechnology, biochip]  Customers: The company's customers include Aral Aromatics, ARKEMA, ConocoPhillips, [NAME], Eastman Chemical Middleburg, [NAME], [NAME], Merck, Roche Diagnostics, SI Group, and Siemens.  Competition: The company's competitors include [NAME], Tosoh Biosep, [NAME], [NAME], Millipore, and Vivascience. | False | True | False | False | False | False | 8077 |  | Announced | 2000-08-19 00:00:00 |  |  | Debt/Loan agreement | Debt | EUR | 0.5 | 0.5 | 0.461799995419769 | [NAME] [NAME] mbH |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.923599990839539 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 165 | PolyAn | GmbH |  |  |  | D | Berlin | B | D-BB | Europe | DIA-LAB | DIA |  |  | MED-RES |  |  | first high-throughput synthetic biochips, highly selective membranes for the petrochemical industry, surfaced immobilized catalysts Cor Competencies: Molecular Surface Engineering (MSE) und dem Surface Molecular Imprinting (SMI),   --> Materialoberflächen mit speziellen chemischen Strukturen versehen und [NAME]. die Ausbeute und Reproduzierbarkeit analytischer [NAME]. Die MSE-Technologie setzt dort an, wo andere [NAME] ihre Grenzen zeigen. erview: Provider of molecular surface engineering technology (MSE). The company provides affinity-membranes, solid phase synthesis, and anti fouling-coatings for biotech-applications. The company's products are designed to improve existing processes such as high-throughput screening and array production. The company also offers synthesis, photochemistry, and analysis services. [[NAME]: nanotechnology, biochip]  Customers: The company's customers include Aral Aromatics, ARKEMA, ConocoPhillips, [NAME], Eastman Chemical Middleburg, [NAME], [NAME], Merck, Roche Diagnostics, SI Group, and Siemens.  Competition: The company's competitors include [NAME], Tosoh Biosep, [NAME], [NAME], Millipore, and Vivascience. | False | True | False | False | False | False | 7058 |  | Announced | 2000-08-18 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 0.5 | 0.5 | 0.461799995419769 | [NAME] [NAME] mbH |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.923599990839539 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 176 | Provecs Medical | GmbH |  |  |  | D | Hamburg | HH | D-HH | Europe | BIO-DR | BIO | CBC | BIO-TH |  | CANCER | Preclinical | Provecs Medical GmbH is a biopharmaceutical company that focuses on development of novel immunotherapies against cancer and infectious diseases. The company aims at development of novel therapy options for cancer patients at high quality of life. Provecs' patented technology platform is based on sophisticated gene transfer technology for the construction of immunotherapeutics. The company's top-down approach from clinical development to molecular and strategic design of new targeted therapies, ensuring straight and cost-controlled processes.  Provecs' product is Immunalon® the immunotherapeutic, used in animal studies leads to generation of three immunostimulatory proteins in the tumor. These can render the tumor visible for immune cells and may provoke the stimulation of a strong immune defense against the tumor cells, capable of destroying the treated and its metastases.  Provecs has alliance with BioReliance Corporation and Avista Capital Partners. The company's investors include: High-Tech Grunderfonds, Peppermint Financial Partners and [NAME]. | True | False | False | False | False | False | 6089 |  | Announced | 2007-08-03 00:00:00 |  |  | VC - Seed | Venture | EUR | 0.5 | 0.5 | 0.685250016848185 | PEPPERMINT. Financial Partners, High-Tech Gründerfonds |  |  |  |  |  | Web |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.37050003369637 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 177 | Cellca | GmbH |  |  |  | D | Laupheim | BW | D-ULM | Europe | BIO-GPX | BIO |  | BIO-STT |  |  |  | Kern der Unternehmensgründung des Start-up-Unternehmens CELLCA GmbH ist, eine neue Technologie zur optimierten biotechnologischen [NAME] zu entwickeln und [NAME]. CELLCA GmbH [NAME] neuen Produktionsverfahren auf Basis stabiler Produktionsstämme. Rentschler kann als Partner diese neue Technologie für eigene Produktionsvorhaben nutzen | True | False | False | False | False | False | 4526 |  | Announced | 2006-05-24 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 8.5 | 8.5 | 10.6726003488573 | regionales Konsortium aus Banken, [NAME] und [NAME] |  | bio-pro http://www.bio-pro.de/de/life/meldungen/02256/index.html |  |  |  | Web |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200 | m2p-labs | GmbH |  |  |  | D | Aachen | NRW | D-MRT | Europe | BIO-DDSA | BIO | ECBC | BIO-STT |  |  |  | m2p-labs is a biotechnology company focused on the support of micro reaction solutions in biochemical engineering. The company offers a unique quantitative micro reactor cultivation system which is applicable in high content screening and bioprocess development.  We offer in house screenings, contract research and high throughput protein production based on our high content screening platform. We provide you with the BioLector-technology to facilitate your screenings and efforts in bioprocess development at your site.  Service We offer in house screenings, contract research and high throughput protein production based on our high content screening platform. | True | False | False | False | False | False | 14102 |  | Announced | 2008-08-13 00:00:00 |  |  | VC - 2nd Round | Venture | EUR | 0.6 | 0.6 | 0.882480022554841 | KfW Mittelstandsbank, Investment Arm; S-UBG Gruppe AG |  | M2p-labs GmbH announced that it has raised €600,000 in its second round of funding on August 13, 2008. The round saw participation from S-UBG Gruppe AG which invested through its fund [NAME] and KfW which invested through its fund ERP-Startfonds along with other investors. |  |  |  | CIQ |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200 | m2p-labs | GmbH |  |  |  | D | Aachen | NRW | D-MRT | Europe | BIO-DDSA | BIO | ECBC | BIO-STT |  |  |  | m2p-labs is a biotechnology company focused on the support of micro reaction solutions in biochemical engineering. The company offers a unique quantitative micro reactor cultivation system which is applicable in high content screening and bioprocess development.  We offer in house screenings, contract research and high throughput protein production based on our high content screening platform. We provide you with the BioLector-technology to facilitate your screenings and efforts in bioprocess development at your site.  Service We offer in house screenings, contract research and high throughput protein production based on our high content screening platform. | True | False | False | False | False | False | 4573 |  | Announced | 2006-07-04 00:00:00 |  |  | VC - Seed | Venture | EUR | 0.6 | 0.6 | 0.75336002462522 | High-Tech Gründerfonds |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 220 | [NAME] | A/S | Headquarters |  |  | DK | Hellerup |  |  | Europe | BIO-DR | BIO | SPC | BIO-TH |  | MULTI | Phase II | [NAME] A/S is a pharmaceutical company involved in the creation of improved, patentable versions of both marketed drugs and high-value development-stage opportunities. The company was founded in December 2007.   [NAME] is built upon a novel prodrug technology, TransCon which conjugates peptides, proteins and small molecules to a carrier molecule in a reversible fashion. Its unique technology of reversibility allows an unmodified active drug to be released (unlinked) in the body in a precise, time-controlled fashion, creating a long-acting effect. The company's chemically controlled delivery approach is a group of unique and proprietary reversible linker reagents in contrast to cleavable linkers used.   [NAME] Transient PEGylation is a molecular engineering technology. The TransPEG conjugates have all the benefit of the drug's original pharmacology while exhibiting a long-acting highly optimized pharmacokinetic profile.   [NAME] has built a high value pipeline with focus on endocrinology, CNS and infectious disease. Its product folio includes: TransCon PEG Growth Hormone (ACP-001), TransCon [NAME], TransCon [NAME], TransCon [NAME], TransCon Hydrogel Pramipexole and TransCon PEG Interferon alpha.   [NAME] investors include: Sofinnova Partners, Gilde Healthcare Partners, and TechnoStart. | True | False | False | False | False | False | 5958 |  | Announced | 2007-12-14 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 17.6 | 17.6 | 24.1208005930561 | Sofinnova Partners, Gilde, Zweite TechnoStart Ventures Fonds | Gilde Healthcare Partners, Sofinnova Partners | [NAME] A/S, a new, privately held biotech company, announced today the closing of its first-round of venture capital financing and the acquisition of Complex Biosystems GmbH, Germany. The Series A financing of EUR 17.6 million was led by Sofinnova Partners (France) and co-led by Gilde Healthcare Partners (The Netherlands), with participation by Zweite TechnoStart Ventures Fonds GmbH & Co. KG (Germany). |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.37050003369637 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 222 | CartiCure | Ltd. |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | ORTH |  | CartiCure is a MedTech company for tissue engineering; developing innovating technology for cartilage repair. CartiCure's technological platform generates original hyaline cartilage-producing cells to be transplanted into damaged joints; efficiently replenishing small and large lesions in the articular cartilage.  Carticure was established in 2005 and is currently based on the premises of the NGT High-Tech Incubator in Nazareth, Israel; all scientific work as well as on-going animal trials are being conducted at the Faculty of Medicine at Technion-Israel Institute of Technology in Haifa, Israel. | False | True | False | False | False | False | 14245 |  | Announced | 2006-03-31 00:00:00 |  |  | Grant | Grant | EUR | 0.85 | 0.85 | 1.06726003488573 | New Generation Technology |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 222 | CartiCure | Ltd. |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | ORTH |  | CartiCure is a MedTech company for tissue engineering; developing innovating technology for cartilage repair. CartiCure's technological platform generates original hyaline cartilage-producing cells to be transplanted into damaged joints; efficiently replenishing small and large lesions in the articular cartilage.  Carticure was established in 2005 and is currently based on the premises of the NGT High-Tech Incubator in Nazareth, Israel; all scientific work as well as on-going animal trials are being conducted at the Faculty of Medicine at Technion-Israel Institute of Technology in Haifa, Israel. | False | True | False | False | False | False | 14246 |  | Announced | 2006-03-31 00:00:00 |  |  | VC - Seed | Venture | EUR | 0.15 | 0.15 | 0.188340006156305 | New Generation Technology |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 30821 |  | Completed | 2010-02-01 00:00:00 | 2010-02-01 00:00:00 |  | Grant | Grant | EUR | 0.6 | 0.6 | 0.79482830541537 | EU Seventh Framework Progamme for Research and Development | EU Seventh Framework Progamme for Research and Development | Published by [NAME] [online], Israel business news - www.globes-online.com - on February 1, 2010  Polymer nanofabrics developer NiCast Ltd. has obtained a three-year €4 million grant from EU Seventh Framework Progamme for Research and Development to head a consortium that will develop a spinal disc product. NiCast will head a group of ten companies and research institutes, and the company's share of the grant is €600,000. |  |  |  | VS | EMH | 2010-05-30 00:00:00 |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.32471384235895 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 6288 |  | Announced | 2008-02-15 00:00:00 |  |  | VC - Later Stage | Venture | EUR | 2.08 | 2.08 | 3.05926407819011 | Infinity Equity |  | Nicast Ltd. announced that it has raised $2.5 million in funding on October 6, 2008. The company will raise $5 million till the beginning of 2009 and a second financing of $5 million till the end of 2009. The round includes participation from existing investors Azritech Ventures and Infinity Venture Capital Fund and a group of private investors. Azritech Ventures invested through its [NAME] |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 5218 |  | Announced | 2007-06-30 00:00:00 |  |  | VC - Bridge | Venture |  |  |  |  | Infinity Venture Capital Fund |  |  |  |  |  | VS |  |  | Amount raised was not disclosed |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.37050003369637 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14257 | 2 Bridge financings in 1 year | Announced | 2006-12-31 00:00:00 |  |  | VC - Bridge | Venture | EUR | 0.83 | 0.83 | 1.04214803406489 | Infinity Equity |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14256 | 2 Bridge financings in 1 year | Announced | 2006-09-30 00:00:00 |  |  | VC - Bridge | Venture | EUR | 0.83 | 0.83 | 1.04214803406489 | Infinity Equity |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14255 |  | Announced | 2006-06-30 00:00:00 |  |  | VC - Bridge | Venture |  |  |  |  | Infinity Equity |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14254 |  | Announced | 2005-11-15 00:00:00 |  |  | VC - Later Stage | Venture |  |  |  |  | Infinity Equity |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.24410000011865 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14253 |  | Announced | 2005-02-14 00:00:00 |  |  | VC - 4rd Round | Venture |  |  |  |  | Azritech Fund, Infinity Equity, TechnoPlus Ventures |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.24410000011865 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14252 |  | Announced | 2004-03-03 00:00:00 |  |  | VC - 3rd Round | Venture | EUR | 0.82 | 0.82 | 1.01999801891991 | Azritech Fund, Infinity Equity, TechnoPlus Ventures |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.24390002307306 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14251 |  | Announced | 2003-04-15 00:00:00 |  |  | VC - 2nd Round | Venture | EUR | 0.28 | 0.28 | 0.31673599371709 | Azritech Fund, TechnoPlus Ventures |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.13119997756104 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14250 |  | Announced | 2002-06-15 00:00:00 |  |  | VC - Bridge | Venture | EUR | 0.21 | 0.21 | 0.198576007915952 | Azritech Fund, TechnoPlus Ventures |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.945600037695009 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14249 |  | Announced | 2001-08-15 00:00:00 |  |  | VC - Bridge | Venture | EUR | 0.55 | 0.55 | 0.492580009089874 | Azritech Fund, TechnoPlus Ventures |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.895600016527043 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14248 |  | Announced | 2001-03-15 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 0.72 | 0.72 | 0.644832011899471 | Azritech Fund, TechnoPlus Ventures |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.895600016527043 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 243 | Nicast |  |  |  |  | ISR | [NAME] |  |  | Europe | MED-TE | MED |  |  | MED-TH | CARDIO |  | Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.  Nicast is currently focused on the development of two products: the AVflo™ and the NovaMesh™.  The AVflo, a CE certified AV access graft, is available in the EU market.  The NovaMesh ventral hernia mesh will be available in the EU market in Q1/2010. | False | True | False | False | False | False | 14247 |  | Announced | 2000-06-15 00:00:00 |  |  | VC - Seed | Venture | EUR | 2.21 | 2.21 | 2.04115597975538 | Azritech Fund, TechnoPlus Ventures |  | Founded in 1995, Nicast develops new vascular products, including artery grafts, and coated stents, based on new nano-scale manufacturing technology. TechnoPlus Ventures (TASE:TNPV) and Azritech Fund invested $2 million in Nicast in 2000. |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.923599990839539 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250 | Auris Medical | AG |  |  |  | CH | [NAME] |  |  | Europe | BIO-DR | BIO | CBC | BIO-TH |  | ENT | Phase II | We at Auris Medical are dedicated to developing novel pharmaceutical therapies (we call them cochlear therapies) to protect hearing and to silence tinnitus. Auris Medical, a Swiss-French biotechnology company developing specific treatments for inner ear disorders, Auris Medical is currently developing two drugs (peptides).   AM-101 for the treatment of one of the most frequent types of tinnitus (excitotoxicity in the cochlea e.g. from noise trauma, long noise exposure, vascularisation problems, certain ototoxic drugs etc.)  AM-111 for the treatment of acute sensorineural hearing loss from acute acoustic trauma, sudden deafness or in middle and inner ear surgery | True | False | False | False | False | False | 12987 |  | Announced | 2008-02-15 00:00:00 |  |  | VC - 2nd Round | Venture | CHF | 11 | 6.929571 | 10.1920132872923 | ZKB Pharma Vision Fund, Lacuna Apo Biotech Fund, undisclosed industrial company | AGF Private Equity | February 15, 2008 - Auris Medical AG, a Swiss-French biotechnology company developing novel therapies for ear disorders, raised CHF 11 million in its Series B financing round from institutional investors. The investment will fund the company’s further expansion and in particular the development of its lead products. The new shares were subscribed by a group of investors led by AGF Private Equity, Paris, and including the two life science investment funds ZKB Pharma Vision Fund, Zurich, and Lacuna Apo Biotech Fund, Luxembourg, as well as an undisclosed industrial company.  In connection with the fund raising, Dr. [NAME] and Prof. [NAME] joined Auris Medical’s Board of Directors. Alain Munoz, MD, is an experienced entrepreneur and consultant in the healthcare industry and is representing AGF Private Equity. Prior to starting his own business in 2000, he was Senior Vice President at Groupe Fournier’s Pharmaceutical Division. [NAME] is professor emeritus in otolaryngology and head and neck surgery, and an internationally renowned expert in the field of inner ear disorders. Up to last year, he was the head of the Department of Otolaryngology, Head and [NAME] of the Technical University of Munich, Germany (“[NAME] rechts der [NAME]”). [NAME], the company’s founder, will continue to serve as Auris Medical’s Chairman of the Board and Managing Director. |  |  |  | NA |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0.629961 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 253 | GeNeuro | S.A. | Headquarters |  |  | CH | Plan-les-Ouates |  | CH-BA | Europe | BIO-DR | BIO | CBC | BIO-TH |  | INFL | TBD | GeNeuro undertakes development of a new therapeutic approach to multiple sclerosis a spin-off company of which bioMérieux will remain partner and shareholder [NAME] will spend the next two years in the Eclosion offices. The GeNeuro approach targets the retroviruses suspected to be a determining cause in the triggering and progression of the disease. This method could result in developing treatments able to stop the advancement of the disease or possibly even to anticipate and cut off its appearance. If clinical trials validate the concept, the first generation of drugs could be brought to market within 6 to 8 years. | True | False | False | False | False | False | 3480 | Biomerieux and GeNeuro SA reach other agreement | Announced | 2008-09-26 00:00:00 |  |  | Other | Other | CHF | 12 | 7.559532 | 11.1185599497734 |  |  | 12.00M for GeNeuro SA Private Placement Geneuro SA announced that it has raised CHF 12 million of funding from existing investor. BioMérieux S.A. on September 26, 2008. As a result of the transaction, the investor will hold minority stake in the company. [NAME]'s price was unchanged after the transaction was announced on 09/26/08. |  |  |  | Web |  |  |  |  |  |  |  |  |  |  |  | -1 | 0 | 0.629961 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 254 | [NAME] | Ltd. | Headquarters |  |  | CH | Bern |  | CH-BA | Europe | BIO-DR | BIO | CBC | BIO-TH |  | INFE | Phase II | [NAME] is a biotechnology company focused on the discovery and development human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases. It was founded in 2006 as a spin-off from Berna Biotech Ltd (a Crucell company).   Kenta's MabIgX technology for the generation and selection of an advanced class of human monoclonal antibodies (MAbs) combines the advantages of classical hybridoma technology with a unique specific heteromyeloma fusion cell line. It has developed a method of selecting B-cells isolated from healthy individuals who have been actively immunized with a vaccine against the target organism, where antibodies are produced. The company's approach of generating hybridomas from human B-cells allows the rapid generation and testing of a variety of therapeutically promising antibodies against a variety of new targets within a short period of time.   Kenta is developing a portfolio of therapeutic monoclonal antibodies that are specifically designed to treat life-th reatening hospital-acquired infections such as serious Pseudomonas aeruginosa or Staphylococcus aureus infections as well as other diseases. The company's pipeline products include: KBPA101 is for the treatment of Pneumonia (Nosocomial Pneumonia); KBRV 201 is for the treatment of respiratory virus infections; KBSA 301 and 302 are in Pre-Clinical stage for Staphylococcus infections; and KBAB 401 is in target identification stage for the treatment of acinetobacter infections.   [NAME] signs agreement with [NAME] for KBSA301. | True | False | False | False | False | False | 22218 | [NAME] raises CHF 12 Million in Series B Private Financing | Announced | 2009-03-12 00:00:00 |  |  | VC - 2nd Round | Venture | CHF | 12 | 7.9494 | 11.0537290381014 | Undisclosed Investor |  | BERNE, Switzerland--(BUSINESS WIRE)--Kenta Biotech today announced that CHF 12 Million (US $10 million) has been raised in a Series B private financing from the existing investors. The proceeds will be used for the ongoing clinical development of KBPA 101 in nosocomial pneumonia and to advance KBSA 201, a fully human IgG monoclonal antibody against methicilin-resistant Staphylococcus aureus, from preclinical into clinical development. Kenta's lead-product KBPA 101, an IgM antibody targeting Pseudomonas aeruginosa, is currently being studied in a Phase IIa study for treatment of nosocomial pneumonia in Switzerland and EU-countries. Results are expected later this year. KBSA 201 is an IgG antibody targeting a clinically highly relevant virulence factor of methicillin-resistant [NAME]. aureus (MRSA). The antibody has shown very promising results in a proof of concept animal model for aggressive systemic S. aureus infections last year and is currently evaluated in additional experimental models for localized infections. Violetta [NAME], CEO of Kenta Biotech stated: "We are delighted to secure this financing, which marks the next phase for our company and enables us to move our highly innovative antibody programmes towards the clinic. Closing this financing round of CHF 12 million in the current difficult financial environment is a significant sign of confidence in Kenta Biotech, its promising pipeline and its employees. In addition, it demonstrates the strength of the company and the commitment of our shareholders. [NAME] is well underway to become a significant player in the fight against life-threatening infections. The proprietary MabIgXr technology will also allow Kenta to diversify into other therapeutic areas, such as cancer". About Kenta Biotech [NAME] is pioneering genuine, fully human monoclonal antibody therapies as life-saving treatments against serious hospital infections, an area of high unmet medical need. Towards this end, its product pipeline is addressing the most aggressive bacteria causing lethal nosocomial infections. Current targets for treatment are major virulence factors of the most difficult to treat bacteria, such as Pseudomonas aeruginosa and [NAME] baumannii and Staphylococcus aureus. All of Kenta Biotech's fully human antibodies are generated based on Kenta's proprietary MAbIgXr technology. Kenta's antibodies selectively target the causative organisms and consequently act through activating and boosting the patient's innate immune system. This mechanism of action works independent of the resistance pattern of the bacteria to antibiotics and without the risks of causing new resistances. These [NAME] are expected to synergistically enhance the efficacy of current treatment options and have a superior safety profile in the management of highly resistant bacteria. [NAME] was founded in 2006 and is financed by independent private investors and management who together hold the company share capital. About Nosocomial Infections In the US and Europe, an estimated 5 to 10 % of patients are expected to develop an infection during their hospital stay. [NAME] estimates that in the US alone 1.8 to 3.7 million patients develop nosocomial infections in an average year, a growing concern according to the Center for Disease Control (CDC). The burden of these hospital-acquired infections is significant, both in terms of mortality and cost. Several studies show that the mortality associated with a Ventilator Associated Pneumonia (VAP) can be as high as 50%. The Association for professionals in infection control and epidemiology (APIC) estimates that the cost of healthcare-associated infections generates annual costs of between $5 and 6 billion and results in more than 100,000 deaths per year in the USA. For additional information please visit our website, www.kentabiotech.com or contact us: Violetta [NAME], CEO of Kenta Biotech +41 31 980 62 53 [NAME], CBO of Ke |  |  |  | MT | AT | 2009-11-16 00:00:00 |  |  |  |  |  |  |  |  |  | 0 | 0 | 0.66245 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 254 | [NAME] | Ltd. | Headquarters |  |  | CH | Bern |  | CH-BA | Europe | BIO-DR | BIO | CBC | BIO-TH |  | INFE | Phase II | [NAME] is a biotechnology company focused on the discovery and development human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases. It was founded in 2006 as a spin-off from Berna Biotech Ltd (a Crucell company).   Kenta's MabIgX technology for the generation and selection of an advanced class of human monoclonal antibodies (MAbs) combines the advantages of classical hybridoma technology with a unique specific heteromyeloma fusion cell line. It has developed a method of selecting B-cells isolated from healthy individuals who have been actively immunized with a vaccine against the target organism, where antibodies are produced. The company's approach of generating hybridomas from human B-cells allows the rapid generation and testing of a variety of therapeutically promising antibodies against a variety of new targets within a short period of time.   Kenta is developing a portfolio of therapeutic monoclonal antibodies that are specifically designed to treat life-th reatening hospital-acquired infections such as serious Pseudomonas aeruginosa or Staphylococcus aureus infections as well as other diseases. The company's pipeline products include: KBPA101 is for the treatment of Pneumonia (Nosocomial Pneumonia); KBRV 201 is for the treatment of respiratory virus infections; KBSA 301 and 302 are in Pre-Clinical stage for Staphylococcus infections; and KBAB 401 is in target identification stage for the treatment of acinetobacter infections.   [NAME] signs agreement with [NAME] for KBSA301. | True | False | False | False | False | False | 4527 |  | Announced | 2006-05-08 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 6.36 | 6.36 | 7.98561626102733 |  |  |  |  |  |  | BW |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 254 | [NAME] | Ltd. | Headquarters |  |  | CH | Bern |  | CH-BA | Europe | BIO-DR | BIO | CBC | BIO-TH |  | INFE | Phase II | [NAME] is a biotechnology company focused on the discovery and development human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases. It was founded in 2006 as a spin-off from Berna Biotech Ltd (a Crucell company).   Kenta's MabIgX technology for the generation and selection of an advanced class of human monoclonal antibodies (MAbs) combines the advantages of classical hybridoma technology with a unique specific heteromyeloma fusion cell line. It has developed a method of selecting B-cells isolated from healthy individuals who have been actively immunized with a vaccine against the target organism, where antibodies are produced. The company's approach of generating hybridomas from human B-cells allows the rapid generation and testing of a variety of therapeutically promising antibodies against a variety of new targets within a short period of time.   Kenta is developing a portfolio of therapeutic monoclonal antibodies that are specifically designed to treat life-th reatening hospital-acquired infections such as serious Pseudomonas aeruginosa or Staphylococcus aureus infections as well as other diseases. The company's pipeline products include: KBPA101 is for the treatment of Pneumonia (Nosocomial Pneumonia); KBRV 201 is for the treatment of respiratory virus infections; KBSA 301 and 302 are in Pre-Clinical stage for Staphylococcus infections; and KBAB 401 is in target identification stage for the treatment of acinetobacter infections.   [NAME] signs agreement with [NAME] for KBSA301. | True | False | False | False | False | False | 8598 |  | Announced | 2005-10-01 00:00:00 |  |  | VC - Individual | Venture | EUR | 9.69 | 9.69 | 12.0553290011497 | Individual Investors |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.24410000011865 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 258 | [NAME] | Ltd. | Headquarters |  |  | CH | Dattwil |  |  | Europe | BIO-DR | BIO | CBC | BIO-TH |  | MET | Preclinical | Vivendy Therapeutics Ltd. is a pharmaceutical company that is engaged in the development of an enzyme replacement therapy (ERT) for [NAME], a rare lysosomal storage disease (LSD). It was founded in March 2006, as a spin-off of Inotech Biotechnologies AG.   [NAME] has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly. Its Enzyme replacement therapy (ERT) is a therapeutic approach for a genetic disorder whereby the protein, naturally lacking, is manufactured separately and given intravenously to the patient on a regular basis.   [NAME] signs patent licensing agreement with Saint Louis University. Its investor's include Aescap Venture, BioMedInvest AG, LSP (Life Sciences Partners) and TVM Capital. | True | False | False | False | False | False | 6368 |  | Announced | 2008-06-24 00:00:00 |  |  | VC - 1st Round | Venture | CHF | 15.7 | 9.8903877 | 14.5467826009535 | Aescap Venture, BioMedinvestor, Life Sciences Partners BV, TVM Capital |  | second closing !!! |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0.629961 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 258 | [NAME] | Ltd. | Headquarters |  |  | CH | Dattwil |  |  | Europe | BIO-DR | BIO | CBC | BIO-TH |  | MET | Preclinical | Vivendy Therapeutics Ltd. is a pharmaceutical company that is engaged in the development of an enzyme replacement therapy (ERT) for [NAME], a rare lysosomal storage disease (LSD). It was founded in March 2006, as a spin-off of Inotech Biotechnologies AG.   [NAME] has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly. Its Enzyme replacement therapy (ERT) is a therapeutic approach for a genetic disorder whereby the protein, naturally lacking, is manufactured separately and given intravenously to the patient on a regular basis.   [NAME] signs patent licensing agreement with Saint Louis University. Its investor's include Aescap Venture, BioMedInvest AG, LSP (Life Sciences Partners) and TVM Capital. | True | False | False | False | False | False | 5954 |  | Announced | 2007-12-31 00:00:00 |  |  | VC - 1st Round | Venture | CHF | 17 | 10.3488163 | 14.1830530878675 |  |  | Vivendy Therapeutics Ltd. Raises CHF 17mio in Series A Round of Financing Basel and Munich, January 14, 2008 - BioMedInvest AG I, LSP Life Sciences Partners and TVM Capital today announced the closing of a CHF 17.0 million Series A round of Vivendy Therapeutics Ltd., a bio-pharmaceutical company located in Basel, Switzerland.   Vivendy Therapeutics Ltd. is a pharmaceutical start up company that is developing an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis (MPS) IVA), a rare lysosomal storage disease. Since it is a rare disease, it applies to orphan-drug-status criteria in the United States, Europe and Japan. The new CEO, Dr. [NAME] states: ”With no drug therapy available, [NAME] patients and their families experience prolonged and significant suffering. The ERT provides [NAME] patients with the enzyme they are naturally lacking and therefore represents the first true therapy for this rare disease. We are pleased that we were able to attract such world class investors to our company at this important time in our development. We are confident that with their support, we will build on our promising preclinical results to advance the clinical development program of an enzyme replacement therapy for [NAME].” |  |  |  | VS |  |  | date taken from VS first closing !!! |  |  |  |  |  |  |  |  | 0 | 0 | 0.6087539 | 1.37050003369637 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 321 | ISTA | S.p.A. | Subsidiary |  |  | IT | Lodi |  |  | Europe | BIO-TPA | BIO |  |  |  |  |  | ISTA is an agricultural company, founded in 2001 as a subsidiary of Dompé group, and then spun off as a separate company in 2008. Molecular biology laboratory and commercial office are headquartered in Lodi (Italy) at Parco Tecnologico Padano, and field trials are placed in several locations around the Italy. By having locations close to our customers, we are better able to experience the needs of those customers, and to develop innovations tailored to their needs. ISTA offers a number of product lines to growers: corn, wheat, rice, barley, alfalfa, soybeans, and sunflower and lab services: selection molecular assistance, fingerprinting, NIR spectroscopy analysis. Using the tools of modern biology, we are constantly looking at ways to maximize the potential of seed so farmers can get more out of each seed. | False | False | False | False | False | False | 4617 |  | Announced | 2004-08-06 00:00:00 |  |  | PIPE | PIPE | USD | 13.3 | 10.69217723 | 13.2999995030982 |  |  | ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced today that it has agreed to sell 1,570,000 shares of its common stock at a price of $8.50 per share to certain institutional investors for aggregate proceeds of approximately $13.3 million, before placem |  | 1.57 |  | NA |  |  |  | 3030 | Dompé Biotec | IT | Europe |  |  |  |  | 0 | 0 | 0.8039231 | 1.24390002307306 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 323 | PharmaKodex | Ltd. | Headquarters |  |  | UK | Wiltshire |  |  | Europe | BIO-DD | BIO | SPC | BIO-TH |  |  | Clinical Phase (unspecified) | PharmaKodex Ltd is a speciality pharmaceuticals company exploiting unique proprietary oral and transdermal drug delivery technologies to develop a pipeline of improved medicinal products (IMPs).   PharmaKodex IMPs include product developments where enhanced oral or transdermal delivery can provide significant benefits for patients, such as better treatment adherence resulting from easy-use, rapid acting medicines with shortened treatment periods and improved efficacy. PharmaKodex will develop and commercialise its products and technologies in an overlapping two component process. The Company’s portfolio of innovative enabling and drug delivery technologies will be used as a basis for both OTC projects and prescription product developments. The Company’s strategy combines its proprietary technologies with existing clinically proven/marketed drugs, either alone or in novel synergistic combinations - improving these drugs use in existing indications or new indications either by speed, route or ease of administration.  Commercialisation of these assets will be in partnership with consumer health and pharmaceutical partners.  PharmaKodex will also selectively license out its technologies for product applications for other pharmaceutical companies. | True | False | False | False | False | False | 8556 |  | Announced | 2006-11-17 00:00:00 |  |  | VC - 1st Round | Venture | GBP | 7.1 | 10.4146776 | 13.0766696219995 | Apposite Capital, SR One (GSK Venture Fund) | Apposite Capital, SR One (GSK Venture Fund) | Newly created PharmaKodex (improves existing pharma and OTC drugs primarily for CNS diseases) grossed £7.1mm ($13.5mm) through its Series A financing. The round was co-led by Apposite Capital and SR One and included participation from the company's founders Unilever Ventures and Vectura Group PLC , which established the joint venture this past May. Representatives from Apposite and SR One join PharmaKodex's board. |  |  |  | VS |  |  | http://www.pharmakodex.co.uk/PDF/PKX_16-11-06.pdf |  |  |  |  |  |  |  |  | -1 | 0 | 1.466856 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 324 | Serentis | Ltd. | Headquarters |  |  | UK | Cambridge |  | UK-CAM | Europe | BIO-DR | BIO | CBC | BIO-TH |  | MULTI | Phase II | Serentis Ltd is a biopharmaceutical company focused on developing proprietary products to address unmet medical needs. It was founded in 2006 with an objective to add maximum value to its projects by undertaking rapid and efficient product development.   [NAME]' internal discovery programs deliver proprietary products which have a lower risk profile than traditional NCE discovery programs. Its internal research is focused on repositioning existing drugs and their templates in new disease areas and indications.   [NAME]' product pipeline includes: SRD285 for wound healing, SRD441 for Atopic dermatitis, SRD326 for [NAME]'s disease; and SRD174 for pruritis.   [NAME]' investors include: MVM Life Science Partners LLP, Novo A/S, and Apposite Capital LLP. | True | False | False | False | False | False | 12640 |  | Announced | 2008-08-12 00:00:00 |  |  | VC - 2nd Round | Venture | GBP | 15.3 | 19.214352 | 28.2604696438944 | Adamant Ventures, Apposite Capital, MVM Life Science Partners, Novo, Scottish Widows Investment Partnership |  | 13. August 2008: Serentis, a privately owned Cambridge biopharma company, has defied the economic climate to close a £10 million financing, expanding the total of its Series A financing to £15.3 million.   The funding will be used to advance and expand the company’s dermatology pipeline. A mix of existing and new investors has backed the business. One of the new investors is Healthcare Private Equity, the Scottish Widows healthcare venture fund.   East Hill, the Boston-based venture capital firm, which became a shareholder in Serentis following the acquisition of Surface Therapeutics last September, also participated in the round.   [NAME], CEO of key investor Adamant Ventures, said: “The Serentis management team has rapidly built an impressive pipeline of promising products targeted at large markets and areas of unmet medical need. Additional projects continue to be evaluated.”  Founded two years ago, Serentis is committed to establishing a clinical-stage development pipeline and to move projects rapidly through proof-of-principle trials.   The pipeline is sourced from in-house, low-risk research programmes and through licensing or acquisition of projects from external sources.   The pipeline includes SRD441, a topical therapy with a new mode of action for the treatment of atopic dermatitis (AD) and SRD174, a topical treatment for pruritus (itch), a distressing symptom of AD. |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1.25584 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 324 | Serentis | Ltd. | Headquarters |  |  | UK | Cambridge |  | UK-CAM | Europe | BIO-DR | BIO | CBC | BIO-TH |  | MULTI | Phase II | Serentis Ltd is a biopharmaceutical company focused on developing proprietary products to address unmet medical needs. It was founded in 2006 with an objective to add maximum value to its projects by undertaking rapid and efficient product development.   [NAME]' internal discovery programs deliver proprietary products which have a lower risk profile than traditional NCE discovery programs. Its internal research is focused on repositioning existing drugs and their templates in new disease areas and indications.   [NAME]' product pipeline includes: SRD285 for wound healing, SRD441 for Atopic dermatitis, SRD326 for [NAME]'s disease; and SRD174 for pruritis.   [NAME]' investors include: MVM Life Science Partners LLP, Novo A/S, and Apposite Capital LLP. | True | False | False | False | False | False | 5166 |  | Announced | 2007-07-03 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 15.12 | 15.12 | 20.7219605094891 | MVM Life Science Partners LLP, Apposite Capital LLP, Novo A/S | MVM Life Science Partners LLP, Apposite Capital LLP and Novo A/S | Cambridge, UK. 3rd July 2007 - Serentis, a Cambridge UK, based biopharmaceutical company focussed on product development announced today that it has completed a £10.3 million ($20.6 million) Series A financing round.  The investment was jointly led by leading Life Science venture funds, MVM Life Science Partners LLP, Apposite Capital LLP and Novo A/S. Dr [NAME] (MVM Life Science Partners LLP), Dr [NAME] (Apposite Capital LLP) and Dr [NAME] (Novo A/S) have joined the board of Serentis.  Established in 2006, Serentis, which has considerable expertise in product discovery and development, will use the funds to progress its lead products into clinical-stage proof-of-principle trials and to expand its development pipeline. Pipeline products will be identified via Serentis' internal, low-risk discovery activities and by licensing near-clinical stage assets and technologies.  "I am delighted that Serentis has received significant support from its syndicate of leading, experienced healthcare investors. The funds raised will provide the financial resources to enable the company to further build its management team and to develop both its internal programs and licensing activities and thereby rapidly build a robust clinical-stage pipeline." commented [NAME], Chief Executive Officer and co-founder of Serentis.  Dr [NAME], Partner at MVM Life Science and Chairman of Serentis commented:  "The management team at Serentis have an impressive track record of innovating and developing low-risk development compounds which can be rapidly progressed to proof-of-principle studies. We are pleased to be able to support the company in order to allow expansion of the management team and progression of the lead compounds."  Dr [NAME], Partner at Apposite Capital, said:  "We are excited to be making this investment in Serentis. The additional financial resources will enable the company to expand its in-licensing capabilities and provide best-in-class development for in-licensed compounds for the benefit of both [NAME] and the originating companies. We are extremely pleased with the progress the company's management team has made during the short time since the company's formation. The company now has the financial resources to build on this success."  Dr [NAME], Partner at Novo A/S quoted:  "Novo A/S are delighted to support the further growth and development of Serentis by co-leading this investment. I look forward to working with the management team and my fellow investor directors to build a very successful UK-based biotech company."  Serentis was advised by [NAME] ([NAME] and [NAME]) and the investors were advised by [NAME] ([NAME]). |  |  |  | VS |  |  | # |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.37050003369637 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 324 | Serentis | Ltd. | Headquarters |  |  | UK | Cambridge |  | UK-CAM | Europe | BIO-DR | BIO | CBC | BIO-TH |  | MULTI | Phase II | Serentis Ltd is a biopharmaceutical company focused on developing proprietary products to address unmet medical needs. It was founded in 2006 with an objective to add maximum value to its projects by undertaking rapid and efficient product development.   [NAME]' internal discovery programs deliver proprietary products which have a lower risk profile than traditional NCE discovery programs. Its internal research is focused on repositioning existing drugs and their templates in new disease areas and indications.   [NAME]' product pipeline includes: SRD285 for wound healing, SRD441 for Atopic dermatitis, SRD326 for [NAME]'s disease; and SRD174 for pruritis.   [NAME]' investors include: MVM Life Science Partners LLP, Novo A/S, and Apposite Capital LLP. | True | False | False | False | False | False | 6918 |  | Announced | 2006-07-01 00:00:00 |  |  | VC - Seed | Venture |  |  |  |  | Apposite Capital, MVM Life Science Partners, [NAME] |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 330 | Nordiag (part of Olerup since 08/2009) | ASA | Subsidiary | NORD | OSE, NO | NO | Oslo |  |  | Europe | BIO-IVD | BIO | CBC | BIO-DIA |  |  |  | NorDiag ASA is a biotechnology company with core competence in automated sample preparation of difficult clinical samples such as faeces, urine and sputum, providing a set-up for downstream applications.   NorDiag's technology can be applied to diagnostics for infectious diseases and cancer. In addition, it is developing genetic tests for the detection of mutations arising in cancer. The company is committed to providing clinical laboratories with novel, accurate, and useful diagnostic tools. Its unique sample preparation, BUGS'n BEADS(TM), is based on patented technology. [NAME] BEADS(TM) eliminates all filtration and centrifugation keeping the nucleic acids intact, pure and free of any amplification inhibitors.   NorDiag's products include [NAME], [NAME], [NAME] DNA, Arrow Viral NA, Bullet Viral NA, [NAME] for TaqMan® 48 set up, Disposable refill tips for NorDiag Bullet 1 mL with filter etc.   NorDiag has collaborations with SSP Primers AB, LinkMed AB, Atlantic Biologicals Diagnostics LLC, [NAME], [NAME], Spartan Bioscience Inc. etc.  novel, proprietary DNA-based technology for cancer testing NorDiag is a biotechnology company aiming to reduce mortality and treatment costs of common cancers through detection at the early, curable phases of cancer development. The Companyâ€™s first product, Genefecâ„¢, enables early detection ofÂ gastrointestinal cancers, including colorectal cancer. This diagnostic product has been sold and reimbursed in Norway since 2002 and was recently introduced in Sweden and Denmark. The company has already achieved clinical acceptance for Genefecâ„¢ in the local Norwegian market with a yearly doubling of sales income since market introduction. NorDiag is now making furtherÂ preparations for bringing the product out into international markets through the Companyâ€™s collaborative partners. | False | False | False | False | False | False | 31963 |  | Completed | 2010-01-18 00:00:00 | 2010-01-18 00:00:00 |  | Rights offering | PIPE | NOK | 8 | 0.9996 | 1.32418395682201 | Existing investors |  |  |  | 8000000 | 1 | BC |  |  |  | 43153 | Olerup International | A | Europe |  |  |  |  | 0 | 0 | 0.12495 | 1.32471384235895 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 330 | Nordiag (part of Olerup since 08/2009) | ASA | Subsidiary | NORD | OSE, NO | NO | Oslo |  |  | Europe | BIO-IVD | BIO | CBC | BIO-DIA |  |  |  | NorDiag ASA is a biotechnology company with core competence in automated sample preparation of difficult clinical samples such as faeces, urine and sputum, providing a set-up for downstream applications.   NorDiag's technology can be applied to diagnostics for infectious diseases and cancer. In addition, it is developing genetic tests for the detection of mutations arising in cancer. The company is committed to providing clinical laboratories with novel, accurate, and useful diagnostic tools. Its unique sample preparation, BUGS'n BEADS(TM), is based on patented technology. [NAME] BEADS(TM) eliminates all filtration and centrifugation keeping the nucleic acids intact, pure and free of any amplification inhibitors.   NorDiag's products include [NAME], [NAME], [NAME] DNA, Arrow Viral NA, Bullet Viral NA, [NAME] for TaqMan® 48 set up, Disposable refill tips for NorDiag Bullet 1 mL with filter etc.   NorDiag has collaborations with SSP Primers AB, LinkMed AB, Atlantic Biologicals Diagnostics LLC, [NAME], [NAME], Spartan Bioscience Inc. etc.  novel, proprietary DNA-based technology for cancer testing NorDiag is a biotechnology company aiming to reduce mortality and treatment costs of common cancers through detection at the early, curable phases of cancer development. The Companyâ€™s first product, Genefecâ„¢, enables early detection ofÂ gastrointestinal cancers, including colorectal cancer. This diagnostic product has been sold and reimbursed in Norway since 2002 and was recently introduced in Sweden and Denmark. The company has already achieved clinical acceptance for Genefecâ„¢ in the local Norwegian market with a yearly doubling of sales income since market introduction. NorDiag is now making furtherÂ preparations for bringing the product out into international markets through the Companyâ€™s collaborative partners. | False | False | False | False | False | False | 26379 | Sarsia Life Science Fund ASacquired NorDiag ASA in a Minority acquisition | Completed | 2009-11-26 00:00:00 | 2009-11-26 00:00:00 |  | Minority acquisition | Strategic Investment | NOK | 11.473 | 1.3148058 | 1.82825207574461 |  |  | NORWAY - Sarsia Life Science Fund AS raised its stake to 45.81% from 27.32% by acquiring an 18.49% stake, or 11.473 mil ordinary shares, in NorDiag ASA, an Oslo-based manufacturer of medical testing equipment, for NOK 1 (USD 0.177) per share, or a total value of NOK 11.473 mil (USD 2.028 mil), in a privately negotiated transaction. |  |  |  | THO | AT | 2010-01-12 00:00:00 | Stake raise to 45.81% from  27.32% is completed | 43153 | Olerup International | A | Europe |  |  |  |  | 0 | 0 | 0.1146 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 330 | Nordiag | ASA | Headquarters | NORD | OSE, NO | NO | Oslo |  |  | Europe | BIO-IVD | BIO | CBC | BIO-DIA |  |  |  | NorDiag ASA is a biotechnology company with core competence in automated sample preparation of difficult clinical samples such as faeces, urine and sputum, providing a set-up for downstream applications.   NorDiag's technology can be applied to diagnostics for infectious diseases and cancer. In addition, it is developing genetic tests for the detection of mutations arising in cancer. The company is committed to providing clinical laboratories with novel, accurate, and useful diagnostic tools. Its unique sample preparation, BUGS'n BEADS(TM), is based on patented technology. [NAME] BEADS(TM) eliminates all filtration and centrifugation keeping the nucleic acids intact, pure and free of any amplification inhibitors.   NorDiag's products include [NAME], [NAME], [NAME] DNA, Arrow Viral NA, Bullet Viral NA, [NAME] for TaqMan® 48 set up, Disposable refill tips for NorDiag Bullet 1 mL with filter etc.   NorDiag has collaborations with SSP Primers AB, LinkMed AB, Atlantic Biologicals Diagnostics LLC, [NAME], [NAME], Spartan Bioscience Inc. etc.  novel, proprietary DNA-based technology for cancer testing NorDiag is a biotechnology company aiming to reduce mortality and treatment costs of common cancers through detection at the early, curable phases of cancer development. The Companyâ€™s first product, Genefecâ„¢, enables early detection ofÂ gastrointestinal cancers, including colorectal cancer. This diagnostic product has been sold and reimbursed in Norway since 2002 and was recently introduced in Sweden and Denmark. The company has already achieved clinical acceptance for Genefecâ„¢ in the local Norwegian market with a yearly doubling of sales income since market introduction. NorDiag is now making furtherÂ preparations for bringing the product out into international markets through the Companyâ€™s collaborative partners. | True | False | False | False | False | False | 22834 | NorDiag ASA. received Follow-on Equity Offering-Financing | Completed | 2008-12-04 00:00:00 | 2009-02-02 00:00:00 |  | Follow-on | Follow-on | USD | 4.78 | 3.249932038 | 4.7800001636599 | - | - |  |  |  |  | CIQ |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0.6799021 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 330 | Nordiag | ASA | Headquarters | NORD | OSE, NO | NO | Oslo |  |  | Europe | BIO-IVD | BIO | CBC | BIO-DIA |  |  |  | NorDiag ASA is a biotechnology company with core competence in automated sample preparation of difficult clinical samples such as faeces, urine and sputum, providing a set-up for downstream applications.   NorDiag's technology can be applied to diagnostics for infectious diseases and cancer. In addition, it is developing genetic tests for the detection of mutations arising in cancer. The company is committed to providing clinical laboratories with novel, accurate, and useful diagnostic tools. Its unique sample preparation, BUGS'n BEADS(TM), is based on patented technology. [NAME] BEADS(TM) eliminates all filtration and centrifugation keeping the nucleic acids intact, pure and free of any amplification inhibitors.   NorDiag's products include [NAME], [NAME], [NAME] DNA, Arrow Viral NA, Bullet Viral NA, [NAME] for TaqMan® 48 set up, Disposable refill tips for NorDiag Bullet 1 mL with filter etc.   NorDiag has collaborations with SSP Primers AB, LinkMed AB, Atlantic Biologicals Diagnostics LLC, [NAME], [NAME], Spartan Bioscience Inc. etc.  novel, proprietary DNA-based technology for cancer testing NorDiag is a biotechnology company aiming to reduce mortality and treatment costs of common cancers through detection at the early, curable phases of cancer development. The Companyâ€™s first product, Genefecâ„¢, enables early detection ofÂ gastrointestinal cancers, including colorectal cancer. This diagnostic product has been sold and reimbursed in Norway since 2002 and was recently introduced in Sweden and Denmark. The company has already achieved clinical acceptance for Genefecâ„¢ in the local Norwegian market with a yearly doubling of sales income since market introduction. NorDiag is now making furtherÂ preparations for bringing the product out into international markets through the Companyâ€™s collaborative partners. | True | False | False | False | False | False | 5069 |  | Announced | 2005-12-14 00:00:00 |  |  | IPO | IPO | NOK | 75 | 9.36423 | 11.650038544111 |  |  | Bergen, December 5 2005;  In connection with the planned listing of the biotechnology company NorDiag ASA on Oslo Stock Exchange, the company has carried out a share issue of 7.5 million shares at a subscription rate of NOK 10 per share. Following the tr |  | 7500000 | 10 | Web |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0.1248564 | 1.24410000011865 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 330 | Nordiag | ASA | Headquarters |  |  | NO | Oslo |  |  | Europe | BIO-IVD | BIO | CBC | BIO-DIA |  |  |  | NorDiag ASA is a biotechnology company with core competence in automated sample preparation of difficult clinical samples such as faeces, urine and sputum, providing a set-up for downstream applications.   NorDiag's technology can be applied to diagnostics for infectious diseases and cancer. In addition, it is developing genetic tests for the detection of mutations arising in cancer. The company is committed to providing clinical laboratories with novel, accurate, and useful diagnostic tools. Its unique sample preparation, BUGS'n BEADS(TM), is based on patented technology. [NAME] BEADS(TM) eliminates all filtration and centrifugation keeping the nucleic acids intact, pure and free of any amplification inhibitors.   NorDiag's products include [NAME], [NAME], [NAME] DNA, Arrow Viral NA, Bullet Viral NA, [NAME] for TaqMan® 48 set up, Disposable refill tips for NorDiag Bullet 1 mL with filter etc.   NorDiag has collaborations with SSP Primers AB, LinkMed AB, Atlantic Biologicals Diagnostics LLC, [NAME], [NAME], Spartan Bioscience Inc. etc.  novel, proprietary DNA-based technology for cancer testing NorDiag is a biotechnology company aiming to reduce mortality and treatment costs of common cancers through detection at the early, curable phases of cancer development. The Companyâ€™s first product, Genefecâ„¢, enables early detection ofÂ gastrointestinal cancers, including colorectal cancer. This diagnostic product has been sold and reimbursed in Norway since 2002 and was recently introduced in Sweden and Denmark. The company has already achieved clinical acceptance for Genefecâ„¢ in the local Norwegian market with a yearly doubling of sales income since market introduction. NorDiag is now making furtherÂ preparations for bringing the product out into international markets through the Companyâ€™s collaborative partners. | True | False | False | False | False | False | 36891 |  | Announced | 2002-06-01 00:00:00 |  |  | VC - Seed | Venture | EUR | 1.35 | 1.35 | 1.27656005088826 |  |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 0.945600037695009 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 331 | Navamedic | ASA | Headquarters | NAVA | OSE, NO | NO | Lysaker |  |  | Europe | BIO-DR | BIO | SPC | BIO-TH |  | MULTI | Marketed | Navamedic ASA is a specialty pharmaceutical company. Navamedic group includes Navamedic ASA and the subsidiary Vitaflo Scandinavia AB (Vitaflo).   [NAME]'s main knowledge areas include Alcohole/Heroin abuse; Dermatology; [NAME]; [NAME]; Medical Nutrition; [NAME]; Ophthalmology; Oral Medicine; Osteoarthritis and Pain. Its subsidiary is Vitaflo Scandinavia AB (Vitaflo).   Navamedic's partners include: [NAME], Bifodan A/S, Chattem, Inc, Dexxon Group, Glycologic Ltd, KV Pharmaceutical Co, [NAME], Medewa, Necura Pharmaceuticals AG, OrphaSwiss GmbH, [NAME], Queisser Pharma GmbH & Co, Smart Practice, Vitaflo Scandinavia AB, [NAME] and so on. | True | False | False | False | False | False | 4498 |  | Announced | 2006-10-13 00:00:00 |  |  | PIPE | PIPE | NOK | 9.9 | 1.23024132 | 1.54469105188361 |  |  | On 12 October 2006 Navamedic ASA has after the close of the marked completed a private placement of a total of 332,800 shares, at a subscription price of NOK 29,70 per share. The private placement was directed to a selected group of professional Norwegia |  | 332800 | 29.7 | NA |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0.1242668 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 331 | Navamedic | ASA | Headquarters | NAVA | OSE, NO | NO | Lysaker |  |  | Europe | BIO-DR | BIO | SPC | BIO-TH |  | MULTI | Marketed | Navamedic ASA is a specialty pharmaceutical company. Navamedic group includes Navamedic ASA and the subsidiary Vitaflo Scandinavia AB (Vitaflo).   [NAME]'s main knowledge areas include Alcohole/Heroin abuse; Dermatology; [NAME]; [NAME]; Medical Nutrition; [NAME]; Ophthalmology; Oral Medicine; Osteoarthritis and Pain. Its subsidiary is Vitaflo Scandinavia AB (Vitaflo).   Navamedic's partners include: [NAME], Bifodan A/S, Chattem, Inc, Dexxon Group, Glycologic Ltd, KV Pharmaceutical Co, [NAME], Medewa, Necura Pharmaceuticals AG, OrphaSwiss GmbH, [NAME], Queisser Pharma GmbH & Co, Smart Practice, Vitaflo Scandinavia AB, [NAME] and so on. | True | False | False | False | False | False | 4499 |  | Announced | 2006-03-31 00:00:00 |  |  | Listing | IPO |  |  |  |  |  |  | BB07: IPO proceeds wrong; 30 mio NOK were raised in Sep 2005 (1,5m shares at NOK20); There will be no share issue or secondary sale of the Company’s Shares in connection with the Listing. |  | 6000000 | 19.8 | Web |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 331 | Navamedic | ASA | Headquarters |  |  | NO | Lysaker |  |  | Europe | BIO-DR | BIO | SPC | BIO-TH |  | MULTI | Marketed | Navamedic ASA is a specialty pharmaceutical company. Navamedic group includes Navamedic ASA and the subsidiary Vitaflo Scandinavia AB (Vitaflo).   [NAME]'s main knowledge areas include Alcohole/Heroin abuse; Dermatology; [NAME]; [NAME]; Medical Nutrition; [NAME]; Ophthalmology; Oral Medicine; Osteoarthritis and Pain. Its subsidiary is Vitaflo Scandinavia AB (Vitaflo).   Navamedic's partners include: [NAME], Bifodan A/S, Chattem, Inc, Dexxon Group, Glycologic Ltd, KV Pharmaceutical Co, [NAME], Medewa, Necura Pharmaceuticals AG, OrphaSwiss GmbH, [NAME], Queisser Pharma GmbH & Co, Smart Practice, Vitaflo Scandinavia AB, [NAME] and so on. | True | False | False | False | False | False | 5040 |  | Announced | 2005-09-01 00:00:00 |  |  | VC - Other Private Equity | Venture | NOK | 30 | 3.745692 | 4.66001541764441 |  |  | Navamedic ASA raised NOK 30 million in a share issue in September 2005, which funds the company's current expansion plans. The company did thus not issue any new capital in connection with the listing. Navamedic has more than 200 shareholders and a suffic |  |  |  | NA |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0.1248564 | 1.24410000011865 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 333 | Anagnostics Bioanalysis | GmbH |  |  |  | A | St.Valentin |  |  | Europe | BIO-TOO | BIO | CBC | BIO-STT | DIA-NIM |  |  | Anagnostics aim is to combine the strengths of the most important methods of molecular diagnostics into a universal technology – the hybcell technology The hyborg may be used for a series of different analyses. DNA analysis is processed on the same device as protein analysis. Reduced investment cost due to optimally used assets is the conclusion Typical fields of application are the identification of infections (virus, bacteria…) or auto-immune diseases (rheumatism…), allergy testing as well as the identification of genetically modified organisms or antibiotics in food.Anagnostics' hybcell is the world's first DNA or protein microarray based on the use of cylinders instead of slides. | True | True | False | False | False | False | 21520 | Anagnostics Bioanalysis received First Round | Completed | 2009-02-27 00:00:00 | 2009-02-28 00:00:00 |  | VC - 1st Round | Venture | EUR | 3 | 3 | 4.17153333764867 | Tecnet capital Technologiemanagement GmbH; PP Capital AG | tecnet Capital Technologiemanagement | Tageszeitungen, [NAME] | 27. Februar 2009 Innovation hybcell-Technologie Rund 3 Mio. Venture Capital für Medizintechnik-Unternehmen tecnet equity und PP Capital steigen bei Anagnostics Bioanalysis ein und finanzieren den [NAME] 2005 entwickelt ein junges Team rund um den Molekulargenetiker und Biochemiker Dr. [NAME] ein Laborgerät, das den Multiplex-Diagnostikmarkt revolutionieren wird. Mit der hybcell-Technologie können Proben wie [NAME] oder [NAME] parallel auf über hundert Merkmale gemessen werden – präzise, schnell und kostengünstig. Anagnostics will mit dieser Technologie in der klinischen Diagnostik [NAME]. Schließlich geht der Trend eindeutig in Richtung Multiplexsysteme, also dem parallelen Messen mehrerer Parameter. Kapital für Marktaufbau und [NAME] [NAME] 2009 ist das 5-köpfige Medizintechnik-Unternehmen diesem ambitionierten [NAME] einen [NAME] näher gekommen. Für die Markteinführung des Laborgeräts (hyborg) und [NAME] entwickelten und patentierten [NAME] (hybcells) wurden in [NAME] equity und der PP Capital zwei Early-stage-Investoren gefunden. |  |  |  | VS | LH | 2009-11-11 00:00:00 |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 334 | f-star | GmbH | Headquarters |  |  | A | Vienna |  |  | Europe | BIO-GPX | BIO | CBC | BIO-STT |  | MULTI |  | f-star Biotechnology Research & Development Company is an antibody engineering company that develops improved therapeutic antibodies and antibody fragments. The company was founded in 2006 to develop and exploit antibody engineering technology.   f-star's proprietary modular antibody technology is based on mutations in non-CDR loops of immunoglobulin domains of constant and variable regions. Its technology allows building additional functionality into therapeutic antibodies or antibody fragments of any size without changing the basic molecular structure of the respective starting molecule. The company's technology is unique in delivering an alternative scaffold with full antibody properties and small size. The technology focuses on two molecular formats such as Fcab(TM) and mAb2.   f-star's Fcab(TM) is a conservative protein engineering scaffold that consists of CH2 and CH3 domains of the antibody, naturally folded as a homo-dimer with two identical antigen binding sites engineered into the CH3 domains. Its mAb2 antibodies are full IgG antibodies with two additional binding sites engineered into the CH3 domains. Its mAb2 antibodies are normal antibodies with a second "pair of arms" capable of performing a therapeutically useful tasks. | True | False | False | False | False | False | 37128 | f-star raises €8m in an Extended Series A Financing co-led by MP Health-care Venture Management and [NAME] | Completed | 2010-01-06 00:00:00 | 2010-01-06 00:00:00 |  | VC - 3rd Round | Venture | EUR | 8 | 8 | 10.5977107388716 | Aescap Venture Management, Atlas Venture, Novo A/S, MP Healthcare Venture Management Inc., [NAME], TVM Capital | Aescap Venture Management | Vienna, Austria, (January 6, 2010) -- f-star Biotechnologische Forschungs-und Entwick-lungsges.m.b.H has announced the closing of an EUR 8 Million Extended Series A financing. The investment round was co-led by MP Healthcare Venture Management (MPH) and [NAME]. f-star’s existing investors comprising Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital also participated in this round. The new financing will support drug discovery and development efforts using f-star’s proprie-tary Modular Antibody Technology. The technology allows the engineering of new antigen binding sites into constant and variable domains of antibodies and has already led to the de-velopment of two promising molecular formats, [NAME]™ and mAb2. Fcabs allow novel thera-peutic candidates to be isolated which, despite being one third the size of immunoglobulin G (IgG), retain all normal antibody functionalities (antigen binding, immune effector functions and long in vivo half life), while mAb2 technology provides the opportunity to add additional functionality, specificity, selectivity or potency to existing antibodies. Dr [NAME], CEO of f-star, commented “We have completed this significant invest-ment round despite the current financial climate and I am pleased to welcome MPH and [NAME] as new shareholders of f-star. Both MPH and [NAME] are investors with a strong strategic focus and the connections they have with their parent pharmaceutical organisations will provide valued support for f-star as it moves product candidates into the clinic. I am also grateful to our existing investors, Atlas, Aescap, Novo and TVM Capital for their continued support and encouragement. This investment, coupled with a rapidly maturing technology and highly committed management and staff, provides a solid platform on which f-star can create novel medicines and grow significant value”. Dr [NAME], Vice President MPH commented: “After an extensive evaluation of next gen-eration antibody companies, f-star stood out with its simple yet powerful technology which has the potential advantages of smaller protein scaffolds while retaining the significant bene-fits of traditional antibodies”. [NAME], Head of Merck Serono Ventures added: “We are excited to join the f-star team and look forward to further supporting the development of f-star's suite of technologies. f-star's platform represents a unique opportunity to generate drug formats that could allow us to leverage our understanding of target biology in our core therapeutic areas”. | Discovery |  |  | BC | UT | 2011-01-14 00:00:00 |  |  |  |  |  |  |  |  |  | -1 | 0 | 1 | 1.32471384235895 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 334 | f-star | GmbH | Headquarters |  |  | A | Vienna |  |  | Europe | BIO-GPX | BIO | CBC | BIO-STT |  | MULTI |  | f-star Biotechnology Research & Development Company is an antibody engineering company that develops improved therapeutic antibodies and antibody fragments. The company was founded in 2006 to develop and exploit antibody engineering technology.   f-star's proprietary modular antibody technology is based on mutations in non-CDR loops of immunoglobulin domains of constant and variable regions. Its technology allows building additional functionality into therapeutic antibodies or antibody fragments of any size without changing the basic molecular structure of the respective starting molecule. The company's technology is unique in delivering an alternative scaffold with full antibody properties and small size. The technology focuses on two molecular formats such as Fcab(TM) and mAb2.   f-star's Fcab(TM) is a conservative protein engineering scaffold that consists of CH2 and CH3 domains of the antibody, naturally folded as a homo-dimer with two identical antigen binding sites engineered into the CH3 domains. Its mAb2 antibodies are full IgG antibodies with two additional binding sites engineered into the CH3 domains. Its mAb2 antibodies are normal antibodies with a second "pair of arms" capable of performing a therapeutically useful tasks. | True | False | False | False | False | False | 5188 |  | Announced | 2007-11-28 00:00:00 |  |  | VC - 2nd Round | Venture | EUR | 9 | 9 | 12.3345003032673 | Aescap Venture, Atlas Venture | Aescap Venture | Antibody Engineering Company F-Star Raises EUR 3.0 million in a Second Closing of its Series A Financing Round from Novo A/S Vienna, Austria (November 28, 2007) -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, today announced that it has raised EUR 3.0 million from Novo A/S in a Second Closing of its Series A financing round, originally co-led by Aescap Venture and Atlas Venture. After this Second Closing, the amount raised in the Series A round increases to EUR 9.0 million. In total, the Company has raised EUR 13.0 million since inception in 2006. |  |  |  | BC |  |  | VS round wrong, according to web 1st round |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.37050003369637 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 334 | f-star | GmbH | Headquarters |  |  | A | Vienna |  |  | Europe | BIO-GPX | BIO | CBC | BIO-STT |  | MULTI |  | f-star Biotechnology Research & Development Company is an antibody engineering company that develops improved therapeutic antibodies and antibody fragments. The company was founded in 2006 to develop and exploit antibody engineering technology.   f-star's proprietary modular antibody technology is based on mutations in non-CDR loops of immunoglobulin domains of constant and variable regions. Its technology allows building additional functionality into therapeutic antibodies or antibody fragments of any size without changing the basic molecular structure of the respective starting molecule. The company's technology is unique in delivering an alternative scaffold with full antibody properties and small size. The technology focuses on two molecular formats such as Fcab(TM) and mAb2.   f-star's Fcab(TM) is a conservative protein engineering scaffold that consists of CH2 and CH3 domains of the antibody, naturally folded as a homo-dimer with two identical antigen binding sites engineered into the CH3 domains. Its mAb2 antibodies are full IgG antibodies with two additional binding sites engineered into the CH3 domains. Its mAb2 antibodies are normal antibodies with a second "pair of arms" capable of performing a therapeutically useful tasks. | True | False | False | False | False | False | 7061 |  | Announced | 2006-12-31 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 1.5 | 1.5 | 1.88340006156305 | [NAME] |  | according to press release was Seed |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 341 | [NAME] | Ltd. |  |  |  | UK | Heslington |  |  | Europe | BIO-DDSA | BIO | ECBC | BIO-STT |  |  |  | [NAME] is the new name for 'The Centre for Biomedical Accelerator Mass Spectrometry' (CBAMS Ltd). Reflecting our aim of accelerating drug development, [NAME] is the world's foremost company using the ultrasensitive platform technology of accelerator mass spectrometry (AMS) in biomedical research and recognised world leader in the field of human microdosing | True | False | False | False | False | False | 30950 |  | Completed | 2010-01-20 00:00:00 | 2010-01-20 00:00:00 |  | VC - 3rd Round | Venture | EUR |  |  |  | Albion Ventures LLP, Frog Capital, Solon Ventures |  | The company will use the new funds to accelerate future growth and to expand it capacity in line with customer demand. |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.32471384235895 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 341 | [NAME] | Ltd. |  |  |  | UK | Heslington |  |  | Europe | BIO-DDSA | BIO | ECBC | BIO-STT |  |  |  | [NAME] is the new name for 'The Centre for Biomedical Accelerator Mass Spectrometry' (CBAMS Ltd). Reflecting our aim of accelerating drug development, [NAME] is the world's foremost company using the ultrasensitive platform technology of accelerator mass spectrometry (AMS) in biomedical research and recognised world leader in the field of human microdosing | True | False | False | False | False | False | 7492 |  | Announced | 2006-12-05 00:00:00 |  |  | VC - 2nd Round | Venture | GBP | 2 | 2.933712 | 3.68356890760551 | Close Ventures, Foursome Investments |  | Further £2m investment for [NAME] and Foursome Investment announce further £2m investment. Close Ventures is pleased to announce that it has invested a further £1.5 million in Xceleron Limited (the Company), the leading provider of innovative early-stage drug development and assessment services to the biotechnology and pharmaceutical industries. Close led a £2 million funding round, with the balance provided by Foursome Investments, as well as directors and management. This additional investment brings the total investment in Xceleron to over £4M, and will fund the Company's expansion in its core UK and US markets. [NAME], a spin-out from York University, provides a range of drug development services to the life-science industries. The Company uses Accelerator Mass Spectrometry, the world's most sensitive analytical device, to provide a range of services to assist in both clinical and pre-clinical development. In particular, [NAME] has pioneered the use of microdosing as a means of testing drugs in humans prior to full clinical trials. The potential benefits of microdosing are considerable. Most importantly, microdosing, now approved by the FDA and EMEA, can reduce the costs and timescales of drug development through predicting early in the development process which drugs will ultimately fail. Close and Foursome together invested £2.0m in April 2005. Since that time, [NAME] has grown rapidly: the Company has doubled the number of staff, increased the run rate of sales by 170%, established a strong presence in the US, signed its first $1m contract and established microdosing - amongst other AMS-based services - as a fundamental analytical tool in drug development. With the market for [NAME]'s services now proven and the opportunities increasing, a further £2.0m was invested to increase the rate of expansion including the move to new premises in the UK, the hire of additional staff, and the enhancement of US operations. The potential market for [NAME]'s services is estimated to be over £200m per annum. "We are delighted with the continued support of our existing investors, Close Ventures and Foursome" said [NAME] [NAME] "this investment allows us to provide the capacity needed to support our substantial growth in sales. We are also excited by our plans to expand in the key US market." "We have been impressed by the progress of [NAME] since we invested. The Company has grown substantially over the past 18 months, has developed its markets and has been led by a first class management team. We are delighted by this additional opportunity to support the Company's growth" said [NAME], Investment Manager at Close Ventures. For further information please visit www.closeventures.co.uk [NAME] [NAME]: 01904 561 561 Ed Lascelles Close [NAME]: 020 7422 7830 Alex Hook Foursome Investments Tel: 020 7833 0555 [NAME] Peregrine Communications Tel: 020 7223 1552 About [NAME] is the world's leading AMS-based bioanalytical services company. With two locations in the UK and one in the USA, [NAME] is a GLP-accredited organisation with unique expertise in its field of ultrasensitive analysis of drugs and their metabolites. [NAME]'s technology has been used to assist 17 of the world's top 20 pharma companies in their drug development activities. More information can be obtained on www.xceleron.com About Close Ventures Close Ventures is one of largest and most successful providers of venture capital in the U.K. Formed in 1996 as part of Close Brothers Group plc, Close Ventures currently manages a portfolio of six VCTs, with funds under management of £235 million. In 2005 and 2006 it was named [NAME] of the Year at the Professional Adviser Awards and VCT Fund Manager of the Year at the Growth Company Awards. The core investment strategy of all of the six funds is to offer investors lower investment risk, whilst providing higher dividend yield and sustained |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1.466856 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 341 | [NAME] | Ltd. |  |  |  | UK | Heslington |  |  | Europe | BIO-DDSA | BIO | ECBC | BIO-STT |  |  |  | [NAME] is the new name for 'The Centre for Biomedical Accelerator Mass Spectrometry' (CBAMS Ltd). Reflecting our aim of accelerating drug development, [NAME] is the world's foremost company using the ultrasensitive platform technology of accelerator mass spectrometry (AMS) in biomedical research and recognised world leader in the field of human microdosing | True | False | False | False | False | False | 8256 |  | Announced | 2006-01-10 00:00:00 |  |  | Grant | Grant |  |  |  |  | European Union | European Union |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 341 | [NAME] | Ltd. |  |  |  | UK | Heslington |  |  | Europe | BIO-DDSA | BIO | ECBC | BIO-STT |  |  |  | [NAME] is the new name for 'The Centre for Biomedical Accelerator Mass Spectrometry' (CBAMS Ltd). Reflecting our aim of accelerating drug development, [NAME] is the world's foremost company using the ultrasensitive platform technology of accelerator mass spectrometry (AMS) in biomedical research and recognised world leader in the field of human microdosing | True | False | False | False | False | False | 7062 |  | Announced | 2005-04-26 00:00:00 |  |  | VC - 1st Round | Venture | GBP | 2 | 2.924832 | 3.63878349154702 | Close Ventures, Foursome Investments |  | [NAME] investment Xceleron today announced the closing of a new funding round of o2m, from close venture management and foursome investment. Close Venture Management led the round with a o1.5 million investment and Foursome Investments joined Close with a further o0.5 million. The new funding will be used to provide working capital and to finance a significant growth phase in Xceleron's development. [NAME], a spin out from the University of York, is the world's foremost company using the nanotechnology of accelerator mass spectrometry (AMS) in drug development. The technologies developed by [NAME] are aimed at speeding up drug development by reducing attrition rates, especially through its innovative microdosing procedures recently endorsed by the FDA and the EMEA. Established in 1997, [NAME] has now proven the efficacy of its technologies and developed its markets. Additionally, regulators have recently endorsed [NAME]'s approach. In order to capitalise on the significant commercial opportunities available, the investment will be used to upgrade [NAME]'s AMS machine, increase the efficiency of its laboratory processes and fund the expansion of its sales activities. [NAME] of Close Venture Management said, "There is significant pressure within the pharmaceutical industry to improve and accelerate drug development, as evidenced by the FDA's Critical Path white paper of last year. [NAME]'s novel approach to drug development is one way to do just this. We are delighted to have the opportunity to support a high quality management team in a niche industry with such potential." [NAME], CEO of Xceleron, commented, "Not only will the funding provided by Close enable [NAME] to expand its operations significantly, but their expertise in assisting companies to manage critical phases in their development will also prove invaluable. I am very excited about the future for [NAME] and, working together with Close and Foursome, we aim to reinforce our position as the leading provider of AMS services to the pharmaceutical and biotechnology industries worldwide." [NAME], financial director of the University of York, said, "This funding is an important step for the company and also marks a key moment in the University's drive to use its research power to support innovation and economic growth. We are delighted to have Close and Foursome alongside us in this venture and hope to see more of such collaborations in the future." Close Venture Management CVM is one of the most successful and longest established Venture Capital Trust (VCT) managers. It was formed in 1996 and currently manages a portfolio of five VCTs, which have to date raised a total of o160 million from private investors. In addition, CVM advises the Healthcare & Leisure Property Fund, an Isle of Man-based open-ended investment company participating in asset-based investments made by its VCTs as well as acting as investment manager to Bamboo Investments plc, an investment company specialising in early stage, high growth businesses, principally in the technology sector. Close Venture Management is one of the largest VCT managers with 8% of the market and concentrates its investment strategy on lower investment risk and higher dividend yield. Close Brothers was voted VCT Group of the Year in the Growth Company Awards 2003 and Best VCT Provider at the Professional Adviser Awards 2005. This investment was made across three of Close's funds including Close's Income & Growth VCT, which recently completed its o45 million fundraising. Foursome Investments Foursome Investments Ltd is an experienced, privately backed venture capital firm established in 1998. Foursome advises its investors on early stage and development capital opportunities in cleantech and health sector enabling technologies. University of York The University of York is ranked 6th in the UK for research quality and is the UK's most research-efficient university. The U |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1.462416 | 1.24410000011865 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 342 | OrthoMimetics | Ltd. | Headquarters |  |  | UK | Cambridge |  | UK-CAM | Europe | BIO-TE | BIO | ECBC | BIO-TH | MED-TH | ORTH | Marketed | Chondromimetic implant for regenerative repair of articular cartilage and bone  Our products are developed from the merging of technologies developed over 30 years by experts in the fields of bone (University of Cambridge) and soft tissue (MIT) repair. This breakthrough proprietary material technology can be incorporated into devices for cartilage, meniscus, ligament and tendon repair, associated with sports and [NAME], providing long-lasting solutions for degenerative joint disease and osteoarthritis. The implants will be delivered using minimally invasive, single-step procedures to provide a precisely controlled, interconnected pore structure for cell migration and attachment which encourages a cell regenerative repair process until the scaffold is fully resorbed. The highly porous and hydrophilic nature of the materials makes Orthomimetics’ products ideally suited for the delivery of autologous blood products and biologics. | True | True | False | False | False | False | 7063 |  | Announced | 2006-12-05 00:00:00 |  |  | VC - 1st Round | Venture | GBP | 5 | 7.33428 | 9.20892226901377 | Eden Capital, Individual Investors, Oxford Capital Partners |  | Orthopedics company OrthoMimetics Ltd. netted £5mm ($9.6mm) in a Series A financing led by Eden Financial with participation from Schroders Investment Management, Oxford Capital Partners, and Sloane Robinson Private Equity.;The company, which was formed as a spin-out from the joint venture Cambridge-MIT Institute , is developing devices to help repair cartilage, ligament, and tendon damage, and reduce the need for joint replacement surgeries. OrthoMimetics will use the funds to continue developing its two lead products-- ChondroMimetic and LigaMimetic for cartilage and ligament repair, respectively. Both were derived from the company's porous, multi-layered tissue-regeneration scaffolds for use with multiple tissue types. Representatives from Eden and Sloane Robinson will take seats on OrthoMimetics' board. |  |  |  | VS |  |  | OrthoMimetics closes £5mm Series A round |  |  |  |  |  |  |  |  | 0 | 0 | 1.466856 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 343 | InterMed Discovery | GmbH | Headquarters |  |  | D | Dortmund | NRW | D-RUHR | Europe | BIO-DDSA | BIO | ECBC | BIO-STT |  | MULTI | Preclinical | InterMed Discovery GmbH is a natural product discovery company, driving through the generation of product candidates for the life science, food and cosmetics industries. It was founded in 2006 as a Management Buy Out from Bayer HealthCare AG. Its vision is to become the leading NP lead-discovery company renowned for its gold standard technology and the partner of choice for top tier companies in life science, food and cosmetics.   InterMed's areas of natural product are specialized for the pharmaceutical and food industries. It offers candidates for pharmaceutical development and helps in find biological substances, additives and extracts for the food industry. It offers services for Pharmaceutical, Crop Science and Food.   InterMed's products include: IMD 026259 for CNS and IMD 026260 for the treatment of cancer, IMD 021365 for the treatment of infections, IMD-009144 for memory, IMD-027060, IMD-011321, etc.   InterMed has collaborations with Lead Discovery Center GmbH (LDC), Biotropics Malaysia Berhad, Khazanah Nasional Berhad, Cognis GmbH and c-LEcta GmbH. | True | False | False | False | False | False | 30780 | InterMed Discovery Receives [NAME] for IMD-026259 | Completed | 2010-01-20 00:00:00 | 2010-01-20 00:00:00 |  | Grant | Grant | EUR |  |  |  | [NAME] for Parkinson |  | Dortmund, Germany, January 20, 2010 - InterMed Discovery (IMD), a world class natural product lead-discovery company, today announced that it has received an award from The Michael J. Fox Foundation for Parkinson’s Research for its programme to develop IMD-026259 as a pharmaceutical treatment to challenge neuro-degeneration in Parkinson’s disease (PD). |  |  |  | VS | EMH |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.32471384235895 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 343 | InterMed Discovery | GmbH | Headquarters |  |  | D | Dortmund | NRW | D-RUHR | Europe | BIO-DDSA | BIO | ECBC | BIO-STT |  | MULTI | Preclinical | InterMed Discovery GmbH is a natural product discovery company, driving through the generation of product candidates for the life science, food and cosmetics industries. It was founded in 2006 as a Management Buy Out from Bayer HealthCare AG. Its vision is to become the leading NP lead-discovery company renowned for its gold standard technology and the partner of choice for top tier companies in life science, food and cosmetics.   InterMed's areas of natural product are specialized for the pharmaceutical and food industries. It offers candidates for pharmaceutical development and helps in find biological substances, additives and extracts for the food industry. It offers services for Pharmaceutical, Crop Science and Food.   InterMed's products include: IMD 026259 for CNS and IMD 026260 for the treatment of cancer, IMD 021365 for the treatment of infections, IMD-009144 for memory, IMD-027060, IMD-011321, etc.   InterMed has collaborations with Lead Discovery Center GmbH (LDC), Biotropics Malaysia Berhad, Khazanah Nasional Berhad, Cognis GmbH and c-LEcta GmbH. | True | False | False | False | False | False | 19275 | Biotropics Malaysia Acquires Key Stake In German-Based Natural Products Lead-Discovery Company | Announced | 2009-01-13 00:00:00 |  |  | VC Corporate - Company | Venture | EUR | 7.44 | 7.44 | 10.3454026773687 | Biotropics Malaysia Berhad | Biotropics Malaysia Berhad | Dortmund, Germany, January 13, 2009 – InterMed Discovery (IMD), an emerging world class natural product lead-discovery company, today announced the close of an equity transaction worth €7.44 million with Biotropics Malaysia Berhad. The round underlines the long-term Strategic Cooperation Agreement between the two Companies, which was announced in September 2008 as a combination of purchase and capital increase. In addition, the agreement solidifies a minority stake held by [NAME] in IMD. The round strengthens IMD’s financial position and paves the way for the next strategic steps in IMD´s development. The money raised in this financing round will be invested in the discovery and development of further functional ingredients and will also be used to co-fund IMD’s pharmaceutical pipeline. In return, the participation provides Biotropics access to IMD’s natural product data base and technology to identify, develop and market suitable active natural ingredients exclusively in key markets including United States and Europe.  “Following IMD’s cooperation agreement with Cognis in February 2008, this additional investment from our strategic partner, Biotropics Malaysia Berhad, will further leverage the discovery and development of innovative natural products and will help to expand our pharmaceutical pipeline,” announce the managing directors of InterMed Discovery Bernard Becker and Dr.[NAME] .“Such endeavours are the logical and consequent next step in boosting IMD’s business model and we look forward to continuing our work with [NAME].” |  |  |  | MM | LH | 2009-10-22 00:00:00 |  |  |  |  |  |  |  |  |  | -1 | 0 | 1 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 343 | InterMed Discovery | GmbH | Headquarters |  |  | D | Dortmund | NRW | D-RUHR | Europe | BIO-DDSA | BIO | ECBC | BIO-STT |  | MULTI | Preclinical | InterMed Discovery GmbH is a natural product discovery company, driving through the generation of product candidates for the life science, food and cosmetics industries. It was founded in 2006 as a Management Buy Out from Bayer HealthCare AG. Its vision is to become the leading NP lead-discovery company renowned for its gold standard technology and the partner of choice for top tier companies in life science, food and cosmetics.   InterMed's areas of natural product are specialized for the pharmaceutical and food industries. It offers candidates for pharmaceutical development and helps in find biological substances, additives and extracts for the food industry. It offers services for Pharmaceutical, Crop Science and Food.   InterMed's products include: IMD 026259 for CNS and IMD 026260 for the treatment of cancer, IMD 021365 for the treatment of infections, IMD-009144 for memory, IMD-027060, IMD-011321, etc.   InterMed has collaborations with Lead Discovery Center GmbH (LDC), Biotropics Malaysia Berhad, Khazanah Nasional Berhad, Cognis GmbH and c-LEcta GmbH. | True | False | False | False | False | False | 7064 |  | Announced | 2006-10-30 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 0.5 | 0.5 | 0.627800020521017 | High-Tech Gruenderfonds Management |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 344 | Glysure | Ltd. |  |  |  | UK | Oxford |  | UK-OXF | Europe | DIA-PM | DIA |  |  | DIA-NIM | MET |  | GlySure has developed a continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of Tight Glycemic Control and [NAME]. | False | True | False | False | False | False | 21338 | GlySure received Later Stage - 3rd | Completed | 2009-07-15 00:00:00 | 2009-07-15 00:00:00 |  | VC - 3rd Round | Venture |  |  |  |  | Delta Partners |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 344 | Glysure | Ltd. |  |  |  | UK | Oxford |  | UK-OXF | Europe | DIA-PM | DIA |  |  | DIA-NIM | MET |  | GlySure has developed a continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of Tight Glycemic Control and [NAME]. | False | True | False | False | False | False | 13281 |  | Announced | 2008-04-28 00:00:00 |  |  | VC - 2nd Round | Venture | EUR | 1.32 | 1.32 | 1.94145604962065 | Delta Partners |  | The company completed a GBP 0.9M round of financing on April 28, 2008; current financing status is being researched. |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 344 | Glysure | Ltd. |  |  |  | UK | Oxford |  | UK-OXF | Europe | DIA-PM | DIA |  |  | DIA-NIM | MET |  | GlySure has developed a continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of Tight Glycemic Control and [NAME]. | False | True | False | False | False | False | 4538 |  | Announced | 2006-05-11 00:00:00 |  |  | VC - 1st Round | Venture | EUR | 1.17 | 1.17 | 1.46905204801918 | Undisclosed Venture Investor(s), Amadeus Capital Partners, Individual Investors |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 345 | Creative Gene Technology | Ltd. |  |  |  | UK | [NAME] |  |  | Europe | BIO-GPX | BIO | CBC | BIO-STT |  |  |  | exploits new techniques in plant genomics (‘DNA chip technology’) and proteomics (high throughput protein identification and analysis) to develop strategic targets for the agrochemical and food industries. Specific targets in the first instance are oil yield in rapeseed and the identification of novel herbicide targets. | True | False | False | False | False | False | 6863 |  | Announced | 2006-03-06 00:00:00 |  |  | VC - Unknown | Venture | GBP | 0.29 | 0.42538824 | 0.534117491602798 | Centre of Excellence for Life Sciences, NorthStar Equity Investors |  |  |  |  |  | BC |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1.466856 | 1.25560004104203 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 347 | Myconostica | Ltd. | Headquarters |  |  | UK | [NAME] |  | UK-MAN | Europe | BIO-IVD | BIO | CBC | BIO-DIA | DIA-NIM |  |  | With recent advances in genomics and real-time PCR technology, rapid molecular testing is now possible and highly desirable. These tests will transform the ability of medics to save both patients' lives and significant expenditure on hospitalisation and drug treatment.   Myconostica has assembled powerful molecular technology in the form of 'molecular beacons' from the world class Public Health Research Institute, Newark NJ , to develop and commercialise a menu of diagnostic tests. A fundamental benefit of the Myconostica processes is the ability to carry out multi-fungal testing within the same process, rapidly. | True | True | False | False | False | False | 20995 | Myconostica Ltd. received Later Stage - 5th | Completed | 2009-09-07 00:00:00 | 2009-09-07 00:00:00 |  | VC - Later Stage | Venture | GBP | 1.7 | 1.909049 | 2.65455384890162 | Amphion Innovations, [NAME], MTI Partners, Nexus Medical Partners |  | Myconostica attracts 1.7 GBP Million in first close of fourth investment round 7th September 2009  Myconostica Ltd, a UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces that it attracted £1.7 million in the first close of its series D investment round.  The funds will be used to launch additional molecular diagnostic products and extend the real-time PCR platforms [NAME] tests are able to operate on. Current diagnostic methods for invasive fungal infections are well-documented as slow and insufficiently specific for optimal patient care. Earlier this year [NAME] launched a real-time PCR kit, MycAssayTM Pneumocystis, for the detection of Pneumocystis, a major cause of pneumonia in AIDS. Using MycAssayTM Pneumocystis in conjunction with Myconostica’s DNA extraction system, MycXtra®, a result can be obtained in under 3 hours. The company shortly plans to launch a test to identify Aspergillus infections, a major cause of mortality in leukaemia and transplant patients and a rapid identification system for fungi found in blood.  [NAME], formed in 2006 as a spin out from the University of Manchester has since attracted a global venture capital investor base, and is developing and commercialising tests based on highly specific genetic ‘signatures’ unique to each disease and allow faster and much more precise identification. These molecular diagnostics tests are simple, rapid and can detect multiple fungi in a single process. Myconostica has a strong portfolio of tests and intellectual property to support its future growth.  The market opportunity for molecular diagnostic testing is rising at >7% annually. The annual potential test numbers estimated in the USA, EU and Japan for Myconostica’s current and forthcoming products exceed 6 million annually, when the market is fully developed. |  |  |  | VS | LH | 2010-01-25 00:00:00 | first close of series D financing |  |  |  |  |  |  |  |  | 0 | 0 | 1.12297 | 1.39051111254956 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 347 | Myconostica | Ltd. | Headquarters |  |  | UK | [NAME] |  | UK-MAN | Europe | BIO-IVD | BIO | CBC | BIO-DIA | DIA-NIM |  |  | With recent advances in genomics and real-time PCR technology, rapid molecular testing is now possible and highly desirable. These tests will transform the ability of medics to save both patients' lives and significant expenditure on hospitalisation and drug treatment.   Myconostica has assembled powerful molecular technology in the form of 'molecular beacons' from the world class Public Health Research Institute, Newark NJ , to develop and commercialise a menu of diagnostic tests. A fundamental benefit of the Myconostica processes is the ability to carry out multi-fungal testing within the same process, rapidly. | True | True | False | False | False | False | 12679 |  | Announced | 2008-08-29 00:00:00 |  |  | VC - 4rd Round | Venture | EUR | 0.73 | 0.73 | 1.07368402744172 | MTI Partners |  |  |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 347 | Myconostica | Ltd. | Headquarters |  |  | UK | [NAME] |  | UK-MAN | Europe | BIO-IVD | BIO | CBC | BIO-DIA | DIA-NIM |  |  | With recent advances in genomics and real-time PCR technology, rapid molecular testing is now possible and highly desirable. These tests will transform the ability of medics to save both patients' lives and significant expenditure on hospitalisation and drug treatment.   Myconostica has assembled powerful molecular technology in the form of 'molecular beacons' from the world class Public Health Research Institute, Newark NJ , to develop and commercialise a menu of diagnostic tests. A fundamental benefit of the Myconostica processes is the ability to carry out multi-fungal testing within the same process, rapidly. | True | True | False | False | False | False | 6277 |  | Announced | 2008-05-20 00:00:00 |  |  | VC - 3rd Round | Venture | GBP | 5.4 | 6.781536 | 9.97428340372744 | Amphion Innovations plc, Nexus Medical Partners, Innoven Partners, [NAME], European Investment Fund, UMIP Premier Fund |  | Myconostica Ltd, a Manchester UK-based medical diagnostic company which specialises in rapid and highly specific tests for life-threatening fungal infections, today announces that it has completed the third close of a $10.8 million (£5.4M) round of financing with a £1m investment from the UMIP Premier Fund (“UPF”). |  |  |  | BC |  |  | Myconostica raised £1 million ($2 million) in a third tranche of its series C round, bringing the total raised in the round to £5.5 million ($10.9 million). The company raised £570,000 ($1.2 million) in a first tranche in July 2007, and £3.9 million ($7.8 |  |  |  |  |  |  |  |  | 0 | 0 | 1.25584 | 1.4708000375914 | 2011-01-18 00:00:00
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 347 | Myconostica | Ltd. | Headquarters |  |  | UK | [NAME] |  | UK-MAN | Europe | BIO-IVD | BIO | CBC | BIO-DIA | DIA-NIM |  |  | With recent advances in genomics and real-time PCR technology, rapid molecular testing is now possible and highly desirable. These tests will transform the ability of medics to save both patients' lives and significant expenditure on hospitalisation and drug treatment.   Myconostica has assembled powerful molecular technology in the form of 'molecular beacons' from the world class Public Health Research Institute, Newark NJ , to develop and commercialise a menu of diagnostic tests. A fundamental benefit of the Myconostica processes is the ability to carry out multi-fungal testing within the same process, rapidly. | True | True | False | False | False | False | 13282 |  | Announced | 2007-07-30 00:00:00 |  |  | VC - 2nd Round | Venture | EUR | 6.41 | 6.41 | 8.78490521599373 | Amphion Innovations |  | The company completed a GBP0.5M round of financing on August 29, 2008; current financing status is being researched. |  |  |  | VS |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 1 | 1.37050003369637 | 2011-01-18 00:00:00